Leukotriene B4 antagonist compounds and method for treatment

Abstract

Novel amidinophenol derivatives of formula (IB) 1

Description

BACKGROUND OF THE INVENTION

[0001] 1. Field of the Invention

[0002] The present invention relates to amidinophenol derivatives, processes for the preparation thereof and the use thereof as leukotriene B4 (LTB4)antagonists, phospholipase A2 inhibitors, and trypsin inhibitors.

[0003] More particularly, it relates to LTB4 antagonists containing an amidinophenol derivative of the formula (IA): 3

[0004] (wherein various symbols are the same meanings as hereafter described), as the active ingredient; to

[0005] amidinophenol derivatives of the formula (IB): 4

[0006] (wherein various symbols are the same meanings as hereafter described) and processes for the preparation thereof; and to LTB4 antagonists, phospholipaseA2 inhibitors and trypsin inhibitors containing a compound of formula (IB) as the active ingredient.

[0007] 2. Description of Related Art

[0008] The metabolic pathways by which various compounds are biosynthesized, in vivo, from arachidonic acid as a common starting material are called the arachidonic acid cascade.

[0009] Lipoxygenase, for example, 5-lipoxygenase, 12-lipoxygenase or 15-lipoxygenase, respectively, acts on arachidonic acid to produce 5-HPETE, 12-HPETE or 15-HPETE from arachidonic acid.

[0010] The above mentioned HPETEs are converted into 5-HETE, 12-HETE or 15-HETE, by converting a peroxy group into a hydroxy group by the action of peroxidase, and 5-HPETE is also converted into LTA4.

[0011] LTA4 is converted into LTB4 or LTC4 by enzymatic reaction (see Biochem. Biophys. Res. Commun., 91, 1266 (1979), Prostaglandins, 19(5), 645).

[0012] Recently a number of properties of LTB4 have been revealed.

[0013] It is understood that LTB4 has strong chemotactic and adhesive activity and degranulation activity on leukocytes (see Nature, 286, 264 (1980), Proc. Nat. Acad. Sci. USA, 78, 3887 (1981)).

[0014] LTB4 also has strong calcium ionophore action, and attacks various cells, and it is considered to accelerate release of metabolites of arachidonic acid from these cells (see J. Biol. Chem, 257, 4746 (1982)).

[0015] High levels of LTB4 have also been found at sites of various inflammations, for example, rheumatism, spondyl arthritis, gout, psoriasis, ulcerative colitis and respiratory tract diseases, thereby demonstrating that LTB4 is closely associated with various inflammations (see J. Clin. Invest., 66, 1166 (1980); Lancet 11 1122-1123 (1982); J. Invest. Dermatol., 82, 477-479 (1984); Gastroenterology 86, 453-460 (1984)).

[0016] It is therefore considered that LTB4 antagonists are useful as anti-inflammatory agents or anti-allergic agents.

[0017] It is known that LTB4 antagonists are also useful for the treatment of rheumatoid arthritis, inflammatory bowel diseases, psoriasis, nonsteroidal anti-inflammatory agent-induced stomach diseases, adult respiratory distress syndrome, cardiac infarction, allergic rhinitis, hemodialysis-induced neutropenia, anaphase asthma (see the specification of the Japanese Patent Kokai No. 5-239008).

[0018] Phospholipase A2 (PLA2) is an enzyme which acts on phospholipids existing in cell membranes. It hydrolyzes an ester bond at the second position of the phospholipids. There are two known kinds of PLA2, membrane-associated PLA2 and pancreatic PLA2.

[0019] Membrane-associated PLA2 acts on phospholipids to release arachidonic acid (AA) from the phospholipids. The AA is converted into prostaglandins, thromboxanes and leukotrienes, which are physiologically active substances inducing various inflammatory diseases and allergic diseases.

[0020] On the other hand, pancreatic PLA2 degrades phospholipids and destroys cell membranes, thereby producing lysolecithin having strong cytotoxicity. Recently, much importance has been attached to pancreatitis, severity in pancreatitis and multiple organ failure induced by this destructive activity on cell membranes.

[0021] It is also reported that membrane-associated PLA2 is also concerned with these diseases.

[0022] Accordingly, the inhibition of PLA2 leads to the suppression of the release of AA, a precursor of various physiologically active substances, and therefore, it is considered to be useful for the prevention and/or the treatment of various inflammatory and allergic diseases. Furthermore, it is considered to be useful for the prevention and/or the treatment of pancreatitis, severity in pancreatitis and multiple organ failure due to the inhibition of the destructive activity on cell membranes.

[0023] It is also known that the inhibition of various proteases such as trypsin, plasmin, thrombin, kallilrein, especially trypsin is useful for the prevention and/or the treatment of disseminated intravascular coagulation, pancreatitis, severity in pancreatitis and multiple organ failure.

[0024] In the specifications of EP-A-588655 and 656349, it is disclosed that cetain amidinophenol compounds of the formula (IA) depicted hereinafter have an inhibitory activity on PLA2 and an inhibitory activity on trypsin and are useful for the prevention and/or the treatment of various inflammatory or allergic diseases, disseminated intravascular coagulation, pancreatitis, severity in pancreatitis and multiple organ failure.

[0025] Several amidinophenol derivatives are known to be LTB4 antagonists. They are disclosed in WO 94/11341, the specification of Japanese Patent Kokai No. 5-239008 and EP-518819. In these applications, it is disclosed that amidinophenyloxy (thio) alkyloxy (thio) benzamide is useful as an LTB4 antagonist.

[0026] For example, it is described in the specification of EP-518819 that compounds of the formula (A): 5

[0027] wherein R1a is amino which is mono- or disubstituted by a substituent selected from an aliphatic hydrocarbon radical, an araliphatic hydrocarbon radical, an aromatic radical, and a cycloaliphatic hydrocarbon radical or is amino which is disubstituted by a divalent aliphatic hydrocarbon radical; R2a is hydrogen, halogen, trifluoromethyl, an aliphatic hydrocarbon radical, or is hydroxy which is etherified by an aliphatic alcohol, araliphatic alcohol, or aromatic alcohol or which is esterified by an aliphatic or araliphatic carboxylic acid;

[0028] R3a is hydrogen or an acyl radical which is derived from an organic carbonic acid, an organic carboxylic acid, a sulfonic acid, or a carbamic acid; X1a and X3a, independently of one another, are oxygen (—O—) or sulphur (—S—);

[0029] X2a is a divalent aliphatic hydrocarbon radical which may be interrupted by an aromatic radical;

[0030] wherein the phenyl rings of formula (A) may be, independently of one another, further substituted by one or more substituents selected from halogen, trifluoromethyl, an aliphatic hydrocarbon radical, hydroxy, and hydroxy which is etherified by an aliphatic alcohol or which is esterified by an aliphatic or araliphatic carboxylic acid;

[0031] wherein aryl moieties in the above definitions may be, independently of one another, further substituted by one or more substituents selected from halogen, trifluoromethyl, an aliphatic hydrocarbon radical, hydroxy, and hydroxy which is etherified by an aliphatic alcohol or which is esterified by an aliphatic or araliphatic carboxylic acid; and

[0032] wherein a cycloaliphatic hydrocarbon radical may be substituted by an aliphatic radical;

[0033] and pharmaceutically acceptable salts thereof are useful as LTB4 antagonist.

[0034] 3. Comparison with the Related Arts

[0035] In the amidinophenyloxy(thio)alkoxy(thio)benzamide compounds represented by EP-518819 as prior art, it can be seen that —X1a—X2a—X3a— must be —O(or S)-alkylene-O(or S)—, with the proviso that the alkylene may be interrupted by an aromatic group.

[0036] It has now been discovered that compounds in which it is essential that the amidinophenyl group is bonded to the phenyl group via an ester or amide group possess useful properties as LTB4 antagonists and as inhibitors of phospholipase A2 and/or trypsin.

SUMMARY OF THE INVENTION

[0037] The present invention relates to the discovery that amidinophenol derivatives defined by formulas (IA) and (IB) have a strong antagonistic activity on LTB4 and thus are useful for the prevention or treatment of diseases induced by LTB4.

[0038] The present invention also relates to the discovery that compounds of formula (IB) have an inhibitory activity on phospholipase A2 and an inhibitory activity on trypsin and thus are useful in preventing or treating conditions associated with the activity of these enzymes, such as various inflammatory and allergic diseases, disseminated intravascular coagulation, pancreatitis, severity in pancreatitits and multiple organ failure.

[0039] Compunds of formula (IA) and processes for the preparation thereof are known and disclosed in EP-A-588655 and EP-A-656349. Compounds of formula (IB) are novel and described below.

DESCRIPTION OF THE INVENTION

[0040] The present invention relates to

[0041] 1) a new amidinophenol derivative of the formula (IB): 6

[0042] is a group of the formula: 7

[0043] wherein R0 is hydrogen, C1-4 alkyl, or C1-4 alkoxy,

[0044] T is NH or oxygen,

[0045] E is a single bond, or a group of the formula: 8

[0046] A0 is selected from the group consisting of a single bond, C1-4 alkylene, -oxy-(C1-4)alkylene-, -thio-(C1-4)alkylene-, C2-8 alkenylene, and C2-8 alkenylene substituted by carboxy or C1-4 alkoxycarbonyl,

[0047] R100, R200, R300 and R400 each independently, is hydrogen or C1-4 alkyl, R is a group of the formula: 9

[0048] is a 4-10 membered hetero ring containing one or two nitrogen atoms, R50, R60 and R70 each independently, is,

[0049] (i) hydrogen,

[0050] (ii) C1-8 alkyl,

[0051] (iii) C2-8 alkenyl

[0052] (iv) —COOR110, wherein R110 is hydrogen, C1-4 alkyl, or C1-4 alkyl substituted by phenyl,

[0053] (v) —(C1-8 alkylene)-COOR110, wherein R110 has the same meaning as defined above,

[0054] (vi) —(C2-8 alkenylene)-COOR110, wherein R110 has the same meaning as defined above,

[0055] (vii) C4-7 cycloalkyl,

[0056] (viii) —(C1-4 alkylene)-(4-7 membered hetero ring containing one oxygen),

[0057] (ix) —(C1-4 alkylene)-(4-7 membered hetero ring containing one nitrogen),

[0058] (x) phenyl,

[0059] (xi) C1-8 alkyl substituted by one or two phenyl,

[0060] (xii) —(C1-4 alkylene)-O-benzoyl,

[0061] (xiii) -(C1-4 alkylene)-CONH—(C1-4 alkylene)-NR120R130,

[0062] (xiv) —(C1-4 alkylene)-COO—(C1-4 alkylene)-NR120R130,

[0063] (xv) —(C1-4 alkylene)-COO-amidinophenyl,

[0064] (xvi) —(C1-4 alkylene)-CONH—(C1-4 alkyl substituted by one or two COOR110), wherein R110 has the same meaning as defined above,

[0065] (xvii) —(C1-4 alkylene)-CONR120R130, or

[0066] (xviii) (C1-4) alkoxy (C1-4) alkyl,

[0067] R80 and R90 each independently, is C1-4 alkyl or —(C1-4 alkylene)-phenyl,

[0068] R120 and R130 each independently, is hydrogen, C1-4 alkyl, or C2-8 alkenyl, with the provisos that:

[0069] (1) R50 and R60 in the formulae (i) and (iii), and R50, R60 and R70 in the formulae (ii) and (iv), do not represent hydrogen at the same time,

[0070] (2) when at least one substituent in R50, R60, R70 and A0 represents a substituent containing —COO-t-Bu, the other groups do not represent groups containing carboxy,

[0071] (3) R120 and R130 do not represent hydrogen at the same time,

[0072] (4) when

[0073] T is oxygen,

[0074] the group: 10

[0075] is the formula (i) as hereinbefore described,

[0076] E is a single bond,

[0077] A0 is a single bond, C1-4 alkylene or vinylene which is optionally substituted by one or two C1-4 alkyl, and

[0078] R is the formula (i) as described above,

[0079] then at least one group in R50, R60 and R70 is

[0080] (viii) —(C1-4 alkylene)-(4-7 membered hetero ring containing one oxygen),

[0081] (ix) —(C1-4 alkylene)-(4-7 membered hetero ring containing one nitrogen),

[0082] (x) phenyl,

[0083] (xi) C1-8 alkyl which is substituted by one or two phenyl,

[0084] (xii) —(C1-4 alkylene)-O-benzoyl,

[0085] (xiii) —(C1-4 alkylene)-CONH—(C1-4 alkylene)-NR120R130,

[0086] (xiv) —(C1-4 alkylene)-COO—(C1-4 alkylene)-NR120R130,

[0087] (xv) —(C1-4 alkylene)-COO-amidinophenyl,

[0088] (xvi) —(C1-4 alkylene)-CONH—(C1-4 alkyl substituted by one or two COOR110), wherein R110 has the same meaning as defined above,

[0089] (xvii) —(C1-4 alkylene)-CONR120R130, or

[0090] (xviii) (C1-4) alkoxy (C1-4) alkyl;

[0091] (5) when

[0092] T is oxygen,

[0093] the group 11

[0094] is the formula (i) as hereinbefore defined,

[0095] E is a single bond,

[0096] A0 is a single bond, C1-4 alkylene or vinylene optionally substituted by one or two C1-4 alkyl, and

[0097] R is the formula (ii) as defined above,

[0098] then R50, R60 and R70 do not represent hydrogen;

[0099] and non-toxic salts thereof or non-toxic acid addition salts thereof,

[0100] 2) a method for the prevention and/or treatment of diseases induced by leukotriene B4, which comprises the administration to a patient of an effective amount of a compound of the formula (IA): 12

[0101] wherein R1 and R2 each independently, is:

[0102] (i) hydrogen, or

[0103] (ii) —COOR4 wherein R4 is C1-3 alkyl;

[0104] A is

[0105] (i) a single bond,

[0106] (ii) C1-4 alkylene, or

[0107] (iii) —C(R5)═C(R6)—, wherein R5 and R6 each independently, is hydrogen or C1-4 alkyl;

[0108] R3 is

[0109] (i) —CON(R7)R8,

[0110] (ii) —CONR9-CH(R7)R8, or

[0111] (iii) 13

[0112] wherein R7 and R8 each independently, is

[0113] (1) hydrogen,

[0114] (2) phenyl,

[0115] (3) —(C1-4 alkylene)-phenyl,

[0116] (4)-(C1-4 alkylene)-phenyl is substituted by one or two —R11—COOR12, wherein R11 is a single bond or C1-8 alkylene, and

[0117] R12 is hydrogen or C1-4 alkyl,

[0118] (5) C1-5 alkyl,

[0119] (6) C2-10 alkenyl containing one to three double bonds,

[0120] (7) —R11a—COOR12,

[0121] wherein R11a is

[0122] (a) a single bond,

[0123] (b) C1-8 alkylene,

[0124] (c) C2-8 alkenylene, or

[0125] (d) C4-8 alkenylene in which one or two carbon atoms in the main chain are replaced by sulfur, and R12 has the same meaning as defined above, or

[0126] (8) C3-7 cycloalkyl;

[0127] R9 is

[0128] (1) hydrogen,

[0129] (2) —R1 1—COOR12, wherein R11 and R12 have the same meanings as defined above, or

[0130] (3) C2-6 alkoxyalkyl;

[0131] the group: 14

[0132] is a 4-7 membered mono hetero ring contain one or two nitrogen;

[0133] R10 is

[0134] (1) hydrogen, or

[0135] (2) —(C1-4 alkylene)-phenyl,

[0136] with the proviso that:

[0137] (1) both R7 and R8 do not represent hydrogen at the same time,

[0138] (2) when at least one group in R7, R8, and R9 represent the group containing —COO-t-Bu, the other groups do not represent the groups containing carboxy;

[0139] or non-toxic salts thereof and non-toxic acid-addition salts thereof,

[0140] 3) processes for the preparation of the compound of the formula (IB),

[0141] 4) LTB4 antagonists containing a compound of the formula (IB) and non-toxic salts thereof or non-toxic acid addition salts thereof, as the active ingredient, and

[0142] 5) phospholipaseA2 and trypsin inhibitors containing a compound of the formula (IB) and non-toxic salts thereof or non-toxic acid addition salts thereof, as the active ingredient.

[0143] The compounds of the invention may form hydrates; it is to be understood that such hydrates form part of the present invention and that references to the compounds in this specification, including the accompanying claims, are to be understood as embracing the hydrates.

[0144] It will be understood that formulae (i) and (ii) for the symbol R may overlap: formula (ii) should be construed as excluding those groupings already embraced by formula (i).

[0145] Throughout the specification, it will be understood by those skilled in the art that all isomers are included in the present invention. For example, the alkyl, alkoxy, alkylene, alkenylene and alkynylene groups include straight-chain and also branched-chain ones, and the double bonds in the alkenylene group include E, Z and EZ mixtures. Accordingly, all isomers produced by the existence of asymmetric carbon atoms are included in the present invention when branched-chain alkyl, alkoxy, alkylene, alkenylene and alkynylene are present.

[0146] Explanation of various symbols in the formula (IB) is given below.

[0147] The C1-3 alkyl group means methyl, ethyl, propyl and the isomers thereof. C1-4 alkyl group means methyl, ethyl, propyl, butyl, and the isomers thereof. C1-5 alkyl group means methyl, ethyl, propyl, butyl, pentyl and the isomers thereof.

[0148] C1-4 alkylene group means methylene, ethylene, trimethylene, tetramethylene and the isomers thereof. C1-8 alkylene group means methylene, ethylene, trimethylene, tetramethylene, pentamethylene, hexamethylene, heptamethylene, octamethylene, and the isomers thereof.

[0149] C2-6 alkoxyalkyl group means ethylene, trimethylene, tetramethylene, pentamethylene, hexamethylene which are interrupted by oxygen except end.

[0150] C4-8 alkenylene group means tetramethylene, pentamethylene, hexamethylene, heptamethylene, octamethylene in which a —CH2—CH2— grouping (which is not at either end of the group) is replaced by a double bond.

[0151] C2-8 alkenylene group containing one to three double bonds means ethylene, trimethylene, tetramethylene, pentamethylene, hexamethylene, heptamethylene or octamethylene in which one to three groupings —CH2—CH2— (except those at each end of the group) are replaced by double bonds.

[0152] C3-7 cycloalkyl group means cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl.

[0153] The 4-7 membered hetero ring containing one or two nitrogen means, for example, pyrrolyl, pyrrolidinyl, imidazolyl, imidazolidinyl, pyridinyl, piperidinyl, pyrazinyl, piperazinyl or pyrimidinyl.

[0154] Further explanation of various symbols in the formula (IB) is given below.

[0155] In the formula (IB), C1-4 alkyl represented by R0, R100, R200, R300, R400, R50, R60, R70, R80, R90, R120 and R130, and that in R0, R100, R200, R300, R400, R50, R60, R70, R80, R90, R120 and R130, means methyl, ethyl, propyl, butyl and the isomers thereof.

[0156] In the formula (IB), C1-4 alkyl represented by R0 and A0, and that in R0 and A0 means methoxy, ethoxy, propoxy, butoxy and the isomers thereof.

[0157] In the formula (IB), C1-4 alkylene represented by A0, and that in A0, means methylene, ethylene, trimethylene, tetramethylene and the isomers thereof.

[0158] In the formula (IB), C2-8 alkenylene represented by A0, and that in A0, means ethylene, trimethylene, tetramethylene, pentamethylene, hexamethylene, heptamethylene, octamethylene and the isomers thereof, having one, two or three double bonds.

[0159] In the formula (IB), C1-8 alkyl represented by R50, R60 and R70, and that in R50, R60 and R70, means methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl and the isomers thereof.

[0160] In the formula (IB), C2-8 alkenyl represented by R50, R60 and R70, and that in R50, R60 and R70, mean methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl and the isomers thereof, having one, two or three double bonds.

[0161] In the formula (IB), 4-7 cycloalkyl represented by R50, R60 and R70, and that in R50, R60 and R70, mean cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl.

[0162] In the formula (IB), examples of the 4-7 membered hetero ring containing one oxygen (which may be partially or fully saturated) represented by R50, R60 and R70, and that in R50, R60 and R70, are furyl, pyranyl, dihydrofuryl, dihydropyranyl, tetrahydrofuryl and tetrahydropyranyl.

[0163] In the formula (IB), examples of the 4-7 membered hetero ring containing one nitrogen (which may be partially or fully saturated) represented by R50, R60 and R70, and that in R50, R60 and R70, are pyrrolyl, pyridinyl, piperidinyl, pyrrolinyl, pyrrolidinyl and dihydropyridinyl.

[0164] In the formula (IB), when R is the formula represented by (vi), examples of the 4-10 membered hetero ring containing one or two nitrogen, (which may be partially or fully saturated) are pyrrolyl, pyridinyl, pyrrolinyl, pyrrolidinyl, dihydropyridinyl, imidazolyl, piperidinyl, imidazolinyl, imidazolidinyl, pyrimidinyl, pyridazinyl, pyrazinyl, indolyl and tetrahydroindolyl.

[0165] Preferred Compound

[0166] Preferred formula (IB) compounds of the present invention are those described in the Examples and the following compounds.

TABLE 1
15
Preferable groups as R
16	17	18	19
20	21
22	23	24
25	26
27
28	29	30	31
32	33	34
35	36

[0167]

TABLE 2
37
Preferable groups as R
38	39	40	41
42	43
44	45	46
47	48
49
50	51	52	53
54	55	56
57	58

[0168]

TABLE 3
59
Preferable groups as R
60	61	62	63
64	65
66	67	68
69	70
71
72	73	74	75
76	77	78
79	80

[0169]

TABLE 4
81
Preferable groups as R
82	83	84	85
86	87
88	89	90
91	92
93
94	95	96	97
98	99	100
101	102

[0170]

TABLE 5
103
Preferabie groups as R
104	105	106	107
108	109
110	111	112
113	114
115
116	117	118	119
120	121	122
123	124

[0171]

TABLE 6
125
Preferabie groups as R
126	127	128	129
130	131
132	133	134
135	136
137
138	139	140	141
142	143	144
145	146

[0172]

TABLE 7
147
Preferable groups as R
148	149	150	151
152	153
154	155	156
157	158
159
160	161	162	163
164	165	166
167	168

[0173]

TABLE 8
169
Preferable groups as R
170	171	172	173
174	175
176	177	178
179	180
181
182	183	184	185
186	187	188
189	190

[0174]

TABLE 9
191
Preferable groups as R
192	193	194	195
196	197
198	199	200
201	202
203
204	205	206
207	208	209
210	211

[0175]

TABLE 10
212
Preferable groups as R
213	214	215	216
217	218
219	220	221
222	223
224
225	226	227	228
229	230	231
232	233

[0176]

TABLE 11
234
Preferable groups as R
235 236
237 238
239 240
241 242
243 244
245 246
247 248
249 250
251 252
253 254
255

[0177]

TABLE 12
256
Preferable groups as R
257 258
259 260
261 262
263 264
265 266
267 268
269 270
271 272
273 274
275 276
277

[0178]

TABLE 13
278
Preferable groups as R
279 280
281 282
283 284
285 286
287 288
289 290
291 292
293 294
295 296
297 298
299

[0179]

TABLE 14
300
Preferabel groups as R
301 302
303 304
305 306
307 308
309 310
311 312
313 314
315 316
317 318
319 320
321

[0180]

TABLE 15
322
Preferable groups as R
323 324
325 326
327 328
329 330
331 332
333 334
335 336
337 338
339 340
341 342
343

[0181]

TABLE 16
344
Preferable groups as R
345 346
347 348
349 350
351 352
353 354
355 356
357 358
359 360
361 362
363 364
365

[0182] Pharmaceutical compositions of the present invention can be prepared using one active ingredient or two or more active ingredients.

[0183] Salts and Acid-additon Salts

[0184] Compounds of the formulae (IA) and (IB) of the present invention may be converted into the corresponding salts and acid-addition salts by known methods. Nontoxic and water-soluble salts are preferred.

[0185] Suitable salts include the salts of alkali metals (sodium, potassium etc.), alkaline-earth metal (calcium, magnesium etc.), ammonium salts, salts of pharmacoligically acceptable organic amines (tetramethyl ammonium, triethylamine, methylamine, dimethylamine, cyclopentylamine, benzylamine, phenetylamine, piperidine, monoethanolamine, diethanolamine, tris (hydroxymethyl)aminomethane, lysine, arginine, N-methyl-D-gulcane etc).

[0186] Suitable acid-addition salts include the salts with inorganic acids such as hydrochloric acid, and the salts with organic acids such as acetic acid, trifluoroacetic acid, lactic acid, tartaric acid, oxalic acid, fumaric acid, maleic acid, citric acid, benzoic acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, toluenesulfonic acid, isethionic acid, glucuronic acid and gluconic acid. Preferred salts include the salts with acids such as hydrochloric acid, methanesulfonic acid, acetic acid and trifluoroacetic acid.

[0187] Preparation of Compounds

[0188] The compounds of the formula (IA) may be prepared by methods known per se, as defined in published applications EP-A-588655 and EP-A-656349. The formula (1B) compounds of the present invention may be prepared by forming an ester or amide bond between a compound of the formula (II): 366

[0189] (wherein the various symbols have the same meanings as hereinbefore defined) with a compound of the formula (III): 367

[0190] (wherein the various symbols have the same meanings as hereinbefore defined). The esterification reaction and the reaction to form an amide are known and can be carried out by known method, for example:

[0191] (1) using an acid halide,

[0192] (2) using a mixed acid anhydride or

[0193] (3) using a condensing agent.

[0194] Esterification can be carried out, for example, as follows:

[0195] (1) the method using an acid halide may be carried out, for example, by reacting a carboxylic acid with an acid halide (e.g., oxalyl chloride, thionyl chloride etc.) in an inert organic solvent (e.g., chloroform, methylene chloride, diethyl ether, tetrahydrofuran etc.) or without a solvent at from −20° C. to the reflux temperature of the solvent, and then by reacting the acid halide obtained with a corresponding alcohol in the presence of a tertiary amine (e.g., pyridine, triethylamine, diethylaniline, diethylaminopyridine etc.) in an inert organic solvent (e.g., chloroform, methylene chloride, diethyl ether, tetrahydrofuran etc.) at a temperature of from 0° C. to 40° C.;

[0196] (2) the method using a mixed acid anhydride may be carried out, for example, by reacting a carboxylic acid and an acid halide (e.g., pivaloyl chloride, tosyl chloride, mesyl chloride etc.) or an acid derivative (e.g., ethyl chloroformate, isobutyl chloroformate etc.) in the presence of a tertiary amine (e.g., pyridine, triethyamine, dimethylaniline, dimethylaminopyridine etc.) in an inert organic solvent (e.g., chloroform, methylene chloride, diethyl ether, tetrahydrofuran etc.) or without a solvent at a temperature of from 0° C. to 40° C., and then by reacting the mixture of acid anhydride obtained with a corresponding alcohol in an inert organic solvent (e.g., chloroform, methylene chloride, diethyl ether, tetrahydrofuran etc.), at a temperature of from O° C. to 40° C.; and

[0197] (3) the method using a condensing agent (e.g., 1,3-dicyclohexylcarbodiimide (DCC), 1-ethyl-3-[(dimethylamino)propyl] cabodiimide (EDC), 2-chloro-1-methypyridinium iodide etc.) may be carried out, for example, by reacting a carboxylic acid with a corresponding alcohol using a condensing agent in the presence or absence of a tertiary amine (e.g., pyridine, triethylamine, dimethylaniline, dimethylaminopyridine etc.) in an inert organic solvent (e.g., chloroform, methylene chloride, dimethyl formamide, diethyl ether etc.) or without a solvent at a temperature of from 0° C. to 40° C.

[0198] The formation of an amide may be accomplished by the same reactions as described above, except the corresponding alcohol is replaced by a corresponding amine.

[0199] The reactions (1), (2) and (3) hereinbefore described may be preferably carried out in an atmosphere of inert gas (e.g., argon, nitrogen etc.) under anhydrous conditions.

[0200] The compounds of the formula (III) may be prepared by the series of reactions depicted in the following Scheme A. 368

[0201] In the Scheme A,

[0202] Rp is t-butyl or benzyloxycarbonyl,

[0203] X10, X20 and X30 each independently, is halogen,

[0204] Ms is methaneosulfonic acid,

[0205] A00 is bond, C1-3 alkylene, oxy-(C1-3) alkylene, thio-(C1-3)alkylene, C2-7 alkenylene, C2-7 alkenylene substituted by carboxy or C1-4 alkoxycarbonyl, and the other symbols have the same meaning as hereinbefore described.

[0206] The reactions in the scheme hereinbefore depicted may be carried out by methods known per se. The compounds of the formulae (II), (IV), (V) and (VI) used as starting materials in this scheme are known per se or may be easily prepared by methods known per se.

[0207] Other starting materials and each of the reagents are known per se or may be prepared by known methods.

[0208] In each reaction in the present specification, products may be purified in a conventional manner. For example, purification may be carried out by distillation at atmospheric or reduced pressure, high performance liquid chromatography, thin layer chromatography or column chromatography using silica gel or magnesium silicate, washing or recrystallization. Purification may be carried out after each reaction, or after a series of reactions.

[0209] Physiological Effects

[0210] As mentioned above, it is understood that LTB4 antagonist is useful as an anti-inflammatory and anti-allergic agent.

[0211] Therefore, compounds of the present invention of formulas (IA) and (IB), having LTB4 antagonistic activity, may be used for the treatment of an animal, preferably a human, as an anti-inflammatory and anti-allergic agent.

[0212] It is known that an LTB4 antagonist is also useful for the prevention and/or treatment of various diseases in animals, including humans. These diseases include rheumatoid arthritis, inflammatory bowel diseases, psoriasis, nonsteroidal anti-inflammatory agent-induced stomach diseases, adult respiratory distress syndrome, cardiac infarction, allergic rhinitis, hemodialysis-induced neutropenia and anaphase asthma.

[0213] The compounds of the formula (IB) also have inhibitory activity on phospholipase and inhibitory activity on trypsin in animals, including humans. Therefore compounds of formula (IB) are useful for the prevention and/or the treatment of various inflammatory, allergic diseases, disseminated intravascular coagulation, pancreatitis, severity in pancreatitis and multiple organ failure in animals, preferably humans.

[0214] Toxicity

[0215] It is confirmed that the toxicity of the active ingredients and non-toxic salts thereof and non-toxic acid addition salts thereof in the present invention is very weak. For example, LD50 of Compound 1 was 117 mg/kg when administered intravenously to male mice. Accordingly, the active substances in the present invention may be considered to be sufficiently safe and suitable for pharmaceutical use.

[0216] For the purpose hereinbefore described, the active ingredient in the present invention and non-toxic salts thereof and non-toxic acid addition salts thereof may be normally administered systemically or partially, usually by oral or parenteral administration.

[0217] The doses to be administered are determined depending upon age, weight, symptom, the desired therapeutic effect, the route of administration, and the duration of the treatment, etc. In the human adult, the doses per person per dose are generally between 1 mg and 1000 mg, by oral administration, up to several times per day, or between 100 μg and 100 mg, by parenteral administration (preferably, intravenously) up to several times per day. As mentioned above, the doses to be used depend upon various conditions. Therefore, there are cases in which doses lower than or greater than the ranges specified above may be used.

[0218] Compounds of the present invention are administered in the form of solid compositions, liquid compositions or other compositions for oral administration, and as injections, liniments or suppositories, etc., for parenteral administration.

[0219] Solid compositions for oral administration include compressed tablets, pills, capsules, dispersible powders, and granules.

[0220] In such compositions, at least one of the active compounds is admixed with at least one inert diluent (such as lactose, mannitol, glucose, hydroxypropyl cellulose, microcrystalline cellulose, starch, polyvinylpyrrolidone, magnesium metasilicate aluminate, etc.).

[0221] These compositions may also comprise, as in normal practice, additional substances other than inert diluents: e.g., lubricating agents (such as magnesium stearate, etc.), disintegrating agents (such as cellulose calcium glycolate, etc.), assisting agents for dissolving (such as arginine, glutamic acid, asparaginic acid, etc.) and stabilizers (human serum albumin, lactose, etc.).

[0222] The tablets or pills may, if desired, be coated with a film of gastric or enteric material (such as sugar, gelatin, hydroxypropyl cellulose, hydroxypropylmethyl cellulose phthalate, etc.).

[0223] Capsules include hard capsules and soft capsules.

[0224] Liquid compositions for oral administration include solutions, emulsions, suspensions, syrups and elixirs.

[0225] These liquid compositions may comprise inert diluents commonly used in the art (purified water, ethanol, etc.).

[0226] Besides inert diluents, such compositions may also comprise adjuvants (such as wetting agents, suspending agents, etc.), sweetening agents, flavoring agents and preserving agents.

[0227] Other compositions for oral administration include spray compositions, which may be prepared by known methods and which comprise one or more of the active compound(s). Spray compositions may comprise additional substances other than inert diluents: e.g. stabilizing agents (sodium sulfate, etc.), isotonic stabilizing agents (sodium chloride, sodium citrate, citric acid, etc.). For preparation of such spray compositions, for example, the method described in the U.S. Pat. No. 2,868,691 or No. 3,095,355 may be used.

[0228] Injections for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions and emulsions.

[0229] In such compositions, one or more of active compound(s) is or are admixed with at least one of inert aqueous diluent(s) (distilled water for injection, physiological salt solution, etc.) or inert non-aqueous diluent(s) (propylene glycol, polyethylene glycol, olive oil, ethanol, POLYSORBATE80 (registered trademark) etc.).

[0230] Injections may comprise furthermore assisting agents such as preserving agents, wetting agents, emulsifying agents, dispersing agents, stabilizing agents (such as human serum albumine, lactose, etc.) and assisting agents for dissolving (arginine, glutamic acid, asparaginic acid, polyvinylpyrrolidone, etc.).

[0231] Usually, they may be sterilized by filtration (a bacteria-retaining filter etc), by incorporation of sterilizing agents in the compositions or by irradiation, or after treated, they may also manufactured in the form of sterile solid compositions, for example, by freeze-drying, which may be dissolved in sterile water or some other sterile diluent(s) for injection immediately before used, and which may be used.

EXAMPLE

[0232] The following Reference Examples and Examples illustrarte the present invention.

[0233] The solvents in parentheses show the developing or eluting solvents used in chromatographic separations and the solvent ratios used are by volume.

Example 1 (A)

[0234] Binding Inhibition Against 3H-LTB4 on the Human Polymorphonuclear Leukocyte (PMN)

[0235] 0.049 ml Hanks balanced salt solution (HBSS), 0.001 ml test compound and 0.05 ml 3H-LTB4 (4 nM) were added to polypropylene tubes and mixed. The reaction was started by addition of a thoroughly mixed PMN cell suspension (1.6×106 cells), followed by incubation at 0° C. for 20 min. The reaction was terminated by the addition of ice-cold HBSS (2.5 ml). PMNs were harvested by vacuum filtration through Whatman GF/C glass fiber filters on a Brandel cell harvester (BRANDEL, M-24R). The filters were then washed 2 times to remove free 3H-LTB4 with 2.5 ml of the ice-cold PBS (−) solution. The filters were transferred to each vial, and equilibrated after adding 8 ml ACS II cocktail (Amersham). The radioactivity was measured by liquid scintillation counter (Aloka, LSC-5100).

[0236] Specific binding of 3H-LTB4 to the LTB4 receptor was defined as total binding minus nonspecific binding. Nonspecific binding was the amount of 3H-LTB4 binding in the presence of 1.5 μM LTB4 instead of the test compound. The inhibitory effect of test compound was calculated from the following equation.

The percentage of inhibition (%)=100−(B1/B0×100)

[0237] B1: Specific 3H-LTB4 binding in presence of test compound

[0238] B0: Specific 3H-LTB4 binding in absence of test compound

[0239] Results

[0240] The results are shown in the following Table 17.

TABLE 17
	European Patent Publication
	No. 588655	binding activity
Compound No.	Compound (Example No.)	(%)
1	1 (i)	91.5
2	1 (m)	76.6
3	1 (p)	75.0
4	1 (aa)	63.7
5	1 (ii)	94.3
6	1 (pp)	71.6
7	1 (qq)	78.0
8	1 (hhh)	82.7
9	1 (lll)	91.6
10	1 (mmm)	86.5
11	2 (g)	76.8
12	2 (p)	95.2
13	2 (u)	100.2
14	2 (w)	96.5
15	2 (cc)	89.1
16	2 (gg)	83.6
17	2 (kk)	93.9
18	3 (f)	87.0
19	4	74.0
20	4 (a)	83.5
21	5 (r)	90.8
22	5 (w)	89.7
23	5 (ff)	78.0
24	European Patent Publication	61.2
	No. 656349
	Example 1 (b)

[0241] The structure of compounds used in the present invention are shown below. 369

Example 1 (B)

[0242] The compounds of the formula (IB), of the present invention have an antagonistic activity on LTB4. The results which are measured by method as hereinbefore described in Example 1 (A), are shown the following Table 18.

TABLE 18
                       binding activity
Compound (Example No.) (%)
2                      79.7
2 (a)                  92.0
2 (b)                  97.9
2 (c)                  103.2
2 (d)                  99.3
2 (e)                  94.5
2 (f)                  91.8
2 (g)                  89.6
2 (h)                  85.4
2 (i)                  69.6
2 (j)                  55.4
2 (k)                  97.7
2 (l)                  81.0
2 (m)                  89.2
2 (n)                  82.8
2 (o)                  85.8
2 (p)                  95.2
2 (q)                  98.0
2 (r)                  80.1
2 (s)                  83.0
2 (t)                  51.5
2 (u)                  67.6
2 (v)                  92.0
2 (w)                  76.7
2 (x)                  94.1
2 (y)                  85.5
2 (z)                  92.8
2 (aa)                 94.4
2 (bb)                 87.3
2 (cc)                 76.7
2 (dd)                 50.8
2 (ee)                 65.3
2 (ff)                 82.4
3                      96.8
4                      73.1
4 (a)                  52.0
5                      89.7
5 (a)                  62.5
5 (b)                  90.2
6                      67.8

Example 1 (C)

[0243] Inhibitory Activity on Phospholipase A2 and on Trypsin

[0244] It has been confirmed that compounds of formula (IB) of the present invention have inhibitory activities on phospholipaseA2 (PLA2) and on trypsin.

[0245] For example, in laboratory tests the following results were obtained.

[0246] Method

[0247] (1) Inhibitory Activity on PLA2

[0248] A reaction solution including 50 mM tris-HCl buffer (pH7.5, 874 μl; containing 100 mM sodium chloride, 1 mM EDTA), 1M calciumchloride (6 μl), 1% bovine serum albumin (10 μl) and 2.5 mM 10PY-PC (10 μl), was prepared. To the solution were added a test compound in various concentration or water (50 μl), and a solution of 10 mU/ml PLA2 (derived from hog pancreas) (50 μl). The appearance of fluorescence was measured (Ex=345 nm, Em=396 nm). Percentage (%) of the strength of fluorescence in the presence of a test compound was calculated when the strength of that in the absence thereof was regarded as 100%, and therefrom IC50 value was calculated. The results are shown in the following Table19.

[0249] (2) Inhibitory Activity on Trypsin

[0250] To a mixture of a 0.2 M HEPES•sodium hydroxide buffer solution (pH 8.0, 100 μl) and distilled water (640 μl), were added a test compound in various concentration or water (10 μl), and a solution of 80 mU/ml trypsin (derived from bovine pancreas) (50 μl) and then the mixture was preincubated for one minute at 30° C. To the solution thus obtained was added 2.5 mM BAPNA (200 μl) and the mixture was incubated at 30° C. The absorbance at 405 nm was measured. Percentage (%) of the absorbance in the presence of a test compound was calculated when the absorbance in the absence thereof was regarded as 100%, and therefrom IC50 value was calculated. The results are shown in the following Table 19.

	TABLE 19
		inhibitory activity	inhibitory activity
	Compound	on PLA2	on trypsin
	(Example No.)	IC50 (μM)	IC50 (μM)
	2	—	0.19
	2 (a)	2.6	0.4
	2 (b)	3.8	0.56
	2 (c)	8.1	0.26
	2 (d)	8.7	0.14
	2 (e)	8.5	0.34
	2 (f)	70	0.10
	2 (g)	53	0.16
	2 (h)	11	0.15
	2 (i)	59	0.14
	2 (j)	—	0.12
	2 (k)	20	0.10
	2 (l)	94	0.12
	2 (m)	18	0.17
	2 (n)	10	0.16
	2 (o)	12	0.14
	2 (p)	29	0.13
	2 (q)	34	0.16
	2 (r)	46	0.16
	2 (s)	44	0.16
	3	4.7	0.12
	4	41	0.16
	4 (a)	—	0.14
	5	—	0.13
	5 (a)	—	0.15
	6	4.5	0.17

[0251] In the methods hereinbefore described,

[0252] 10PY-PC represents 3′-palmitoyl-2-(1-pyrenedecanoyl)-L-(α-phosphatidycholine,

[0253] HEPES represents 4-2-hydroxyethyl)-1-piperazineethanesulfonic acid, and

[0254] BAPNA represents α-N-benzoyl-DL-arginine-p-nitroanilide hydrochloride.

[0255] Preparation of New Compounds

[0256] The following Reference Examples and Examples illustrate the preparation of new compounds of formula (IB).

Reference Examples 1

[0257] N-(2-Propenyl)-N-ethoxycarbonylmethyl-4-benzyloxycarbonylphenoxyacetamide. 370

[0258] A solution of 4-benzyloxycarbonylphenoxyacetic acid (4.29 g) in thionyl chloride (10 ml) was refluxed for 15 min. After an excess amount of solvent was distilled off, product was dissolved in dichloromethane. And this solution was added dropwise to a solution of N-(2-propenyl)-N-ethoxycarbonylmethylamine (2.14 g) in pyridine under cooling with ice. After the solution was stirred for 30 min at room temperature, the solution was poured into ice water. The mixture was extracted with ethyl acetate. The extract was washed with a solution of 1N hydrochloric acid, water and a saturated aqueous solution of sodium chloride, successively, and then evaporated. The residue was then purified by silica gel column chromatograhy to obtain the title compound (5.96 g) having the following physical data:

[0259] TLC:Rf 0.43 (hexane:ethyl acetate=3:2)

Reference Example 2

[0260] N-(2-Propenyl)-N-ethoxycarbonylmethyl-4-carboxyphenoxyacetamide 371

[0261] Methanesulfonic acid (28 ml) was added to the compound prepared in Reference Example 1 (5.69 g) under cooling at 0° C. After reaction, the solution was stirred for one hour at room temperature, poured into ice water and extracted with ethyl acetate. The organic layer was washed with water, and a saturated aqueous solution of sodium chloride, successively, and then evaporated. The residue was purified by silica gel column chromatography to obtain the title compound (4.31 g) having the following physical data.

[0262] TLC:Rf 0.35 (hexane:ethyl acetate=1:1)

Example 2

[0263] N-(2-propenyl)-N-ethoxycarbonylmethyl-4-(4-amidinophenoxycarbonyl)phenoxyacetamide acetate 372

[0264] To a pyridine solution of amidinophenol (1.72 g) and the compound prepared in Reference Example 2 (3.21 g) was added DCC (3.09 g) and stirred overnight at room temperature. The reaction solution was filtered and the filtrate was evaporated. The residue was purified by silica gel column chromatography and was formed into acetate by a conventional manner to obtain the title compound having the following physical data.

[0265] TLC:Rf 0.41 (chloroform:methanol:acetic acid=10:2:1),

[0266] NMR (CD3OD): δ 8.14(2H, d, J=9.0 Hz), 7.90(2H, d, J=9.0 Hz), 7.49(2H, d, J=9.0 Hz), 7.08(2H, d, J=9.0 Hz), 5.68-6.07(1H, m), 5.17-5.37(2H, m), 4.93 and 5.02(2H, s, ratio=7:10), 4.03-4.28(6H, m), 1.26 and 1.29(3H, t, J=7.0 Hz).

Example 2 (a)˜2 (ff)

[0267] By the same procedure as Reference Examples 1-2 and Example 2, the compound having the following physical data was obtained.

Example 2 (a)

[0268] 373

[0269] TLC:Rf 0.57 (chloroform:methanol:acetic acid=10:2:1),

[0270] NMR (CD3OD): δ 2.60(2H, t, J=8.0 Hz), 2.98(2H, t, J=8.0 Hz), 5.17(2H, s), 6.99-7.02(2H, m), 7.09-7.16(5H, m), 7.30(5H, s), 7.38(1H, d, J=9.0Hz), 7.43(1H, s), 7.48(2H, d, J=8.0 Hz), 7.98(2H, d, J=8.0 Hz).

Example 2 (b)

[0271] 374

[0272] TLC:Rf 0.60 (chloroform:methanol:acetic acid=10:2:1),

[0273] NMR (CD3OD): δ 2.41(2H, t, J=7.0 Hz), 3.00(2H, t, J=7.0 Hz), 4.69(2H, s), 5.23(2H, s), 7.09-7.42(14H, m), 7.43(2H, d, J=8.0 Hz), 7.98(2H, d, J=8.0 Hz).

Example 2 (c)

[0274] 375

[0275] TLC:Rf 0.53 (chloroform:methanol:acetic acid=10:2:1),

[0276] NMR (CD3OD): δ 8.0(2H, d, J=8.0 Hz), 7.50(2H, d, J=8.0 Hz), 7.46(1H, s), 7.40(1H, d, J=8.0 Hz), 7.24(5H, s), 7.12(1H, s), 7.10(1H, d, J=8.0 Hz), 4.61(2H, s), 4.22(2H, q, J=8.0 Hz), 3.00(2H, t, J=9.0 Hz), 2.61(2H, t, J=9.0 Hz), 1.30(3H, t, J=8.0 Hz).

Example 2 (d)

[0277] 376

[0278] TLC:Rf 0.45 (chloroform:methanol:acetic acid=10:2:1),

[0279] NMR (CD3OD): δ 8.00(2H, d, J=8 Hz), 7.80(1H, d, J=16 Hz), 7.75(2H, d, J=8 Hz), 7.50(2H, d, J=8 Hz), 7.35(2H, d, J=8 Hz), 7.30-7.20(5H, m), 6.70(1H, d, J=16 Hz), 4.65(2H, s), 4.25(2H, q, J=7 Hz), 1.30(3H, t, J=7 Hz).

Example 2 (e)

[0280] 377

[0281] TLC:Rf 0.45 (chloroform:methanol:acetic acid=10:2:1),

[0282] NMR (CD3OD): δ 1.30(3H, t, J=7.0 Hz), 2.18(3H, s), 4.31(2H, q, J=7.0 Hz), 4.77(2H, m), 5.02(1H, t, J=4.0 Hz), 7.39-7.61(8H, m), 7.89(2H, d, J=9.0 Hz), 8.02(2H, d, J=9.0 Hz), 8.22(2H, d, J=9.0 Hz).

Example 2 (f)

[0283] 378

[0284] TLC:Rf 0.43 (chloroform:methanol:acetic acid=10:2:1),

[0285] NMR (CD3OD): δ 8.00-7.80(7H, m), 7.50(2H, d, J=8.5 Hz), 6.90(1H, d, J=16 Hz), 4.60(1H, dd, J=4.5, 4.5 Hz), 4.20(2H, q, J=6.5 Hz), 4.15(2H, q, J=6.5 Hz), 2.50(2H, t, J=7.5 Hz), 2.30(1H, m), 2.10(1H, m), 1.30(3H, t, J=6.5 Hz), 1.25(3H, t, J=6.5 Hz).

Example 2 (g)

[0286] 379

[0287] TLC:Rf 0.46 (chloroform:methanol:acetic acid=10:2:1),

[0288] NMR (CD3OD): δ 8.00-7.90(5H, m), 7.65(2H, d, J=8 Hz), 7.50(2H, d, J=8 Hz), 4.65(1H, dd, J=4.5, 4.5 Hz), 4.20(2H, q, J=6.5 Hz), 4.15(2H, q, J=6.5 Hz), 2.50(2H, t, J=7.5 Hz), 2.30(1H, m), 2.25(3H, m), 2.10(1H, m), 1.30(3H, t, J=6.5 Hz), 1.25(3H, t, J=6.5 Hz).

Example 2 (h)

[0289] 380

[0290] TLC:Rf 0.48 (chloroform:methanol:acetic acid=15:2:1),

[0291] NMR (CD3OD): δ 8.24(2H, d, J=8.5 Hz), 7.95(2H, d, J=8.5 Hz), 7.62(2H, d, J=8.0 Hz), 7.55(2H, d, J=8.0 Hz), 7.35(1H, s), 6.85(1H, dt, J=7.5, 15.0 Hz), 5.93(1H, d, J=15.0 Hz), 4.28(4H, q, J=7.5 Hz), 4.18(2H, d, J=7.5 Hz), 3.23(2H, d, J=7.5 Hz), 2.14(3H, s), 1.26(6H, t, J=7.5 Hz), 1.23(3H, t, J=7.5 Hz).

Example 2 (i)

[0292] 381

[0293] TLC:Rf 0.43 (chloroform:methanol:acetic acid=10:2:1),

[0294] NMR (CD3OD): δ 8.24 and 8.26(2H, d, J=9.0 Hz), 7.81(1H, d, J=18.0 Hz), 7.75(2H, d, J=9.0 Hz), 7.58 and 7.66(2H, d, J=9.0 Hz), 7.37(2H, d, J=9.0 Hz), 6.73(1H, d, J=18.0 Hz), 5.77-5.96(1H, m), 5.22-5.34(2H, m), 4.12-4.28(4H, m), 3.96-4.00(2H, m), 1.20 and 1.30(3H, t, J=7.0 Hz).

Example 2 (j)

[0295] 382

[0296] TLC:Rf 0.44 (chloroform:methanol:acetic acid=10:2:1),

[0297] NMR (CD3OD): δ 8.18(2H, d, J=9.0 Hz), 7.90(2H, d, J=9.0 Hz), 7.50(2H, d, J=9.0 Hz), 7.17(2H, d, J=9.0 Hz), 4.70(2H, s), 4.55(1H, dd, J=9.5, 5.0 Hz), 4.18(2H, q, J=7.0 Hz), 4.11(2H, q, J=7.0 Hz), 2.40(2H, t, J=7.0 Hz), 1.97-2.32(2H, m), 1.27(3H, t, J=7.0 Hz), 1.23(3H, t, J=7.0 Hz).

Example 2 (k)

[0298] 383

[0299] TLC:Rf 0.48 (chloroform:methanol:acetic acid=15:2:1),

[0300] NMR (CD3OD): δ 8.22(2H, d, J=8.0 Hz), 7.92(2H, d, J=8.0 Hz), 7.60(2H, d, J=8.0 Hz), 7.56(2H, d, J=8.0 Hz), 7.37(1H, brs), 4.27(4H, q, J=7.5 Hz), 4.13(2H, q, J=7.5 Hz), 3.47(2H, s), 2.16(3H, s), 1.25(6H, t, J=7.5 Hz), 1.22(3H, t, J=7.5 Hz).

Example 2 (l)

[0301] 384

[0302] TLC:Rf 0.49 (chloroform:methanol:acetic acid=10:2:1),

[0303] NMR (CD3OD): δ 7.98(1H, s), 7.90(2H, d, J=9.0 Hz), 7.58(4H, m), 7.48(2H, d, J=9.0 Hz), 5.78-5.96(1H, m), 5.23-5.32(2H, m), 4.22(2H, q, J=7.0 Hz), 4.20(2H, s), 3.98-4.03(2H, m), 2.24(3H, s), 1.30(3H, t, J=7.0 Hz).

Example 2 (m)

[0304] 385

[0305] TLC:Rf 0.38 (chloroform:methanol:acetic acid=10:1:1),

[0306] NMR (CD3OD): δ 8.20(2H, d, J=8.4 Hz), 7.92(2H, d, J=8.8 Hz), 7.74(2H, d, J=8.4 Hz), 7.55(2H, d, J=8.8 Hz) 7.25(3H, m), 6.32(1H, d, J=14.6 Hz), 4.55(1H, m), 4.20(2H, q, J=7.2 Hz), 4.14(2H, q, J=7.0 Hz), 2.72(3H, s), 2.45(2H, t, J=7.4 Hz), 2.36-1.90(2H, m), 1.29(3H, t, J=7.2 Hz), 1.25(3H, t, J=7.0 Hz).

Example 2 (n)

[0307] 386

[0308] TLC:Rf 0.39 (chloroform:methanol:acetic acid=10:1:1),

[0309] NMR (CD3OD): δ 8.18(2H, d, J=8.4 Hz), 7.92(2H, d, J=8.8 Hz), 7.73(2H, d, J=8.4 Hz), 7.53(2H, d, J=8.8 Hz), 7.50-7.15(2H, m), 7.05(1H, d, J=14.5 Hz), 6.75-6.55(1H, m), 6.03-5.81(1H, m), 5.32-5.14(2H, m), 4.20(2H, q, J=7.2 Hz), 4.30-4.10(4H, m), 1.94(3H, s), 1.28(3H, t, J=7.2 Hz).

Example 2 (o)

[0310] 387

[0311] TLC:Rf 0.50 (chloroform:methanol:acetic acid=10:2:1),

[0312] NMR (CD3OD): δ 8.20(2H, d, J=8.5 Hz), 7.90(2H, d, J=11.5 Hz), 7.60(2H, d, J=8.5 Hz), 7.55(2H, d, J=11.5 Hz), 7.35(1H, br.s), 5.70(1H, m), 5.15(2H, m), 4.25(4H, q, J=7 Hz), 3.10(2H, d, J=7 Hz), 2.15(3H, s), 1.95(3H, s), 1.25(6H, t, J=7HZ).

Example 2 (p)

[0313] 388

[0314] TLC:Rf 0.50 (chloroform:methanol:acetic acid=10:1:1),

[0315] NMR (CD3OD): δ 7.94(2H, d, J=8.0 Hz), 7.89(2H, d, J=8.5 Hz), 7.72(2H, d, J=8.5 Hz), 7.44(2H, d, J=8.0 Hz), 6.49(1H, s), 4.64(1H, m), 4.23(2H, q, J=7.5 Hz), 4.14(2H, q, J=7.0 Hz), 2.74(3H, s), 2.66(3H, s), 2.52(2H, t, J=7.0 Hz), 2.32(2H, m), 2.14(2H, m), 1.30(3H, t, J=7.0 Hz), 1.25(3H, t, J=7.5 Hz).

Example 2 (q)

[0316] 389

[0317] TLC:Rf 0.50 (chloroform:methanol:acetic acid=10:1:1),

[0318] NMR (CD3OD): δ 7.89(2H, d, J=8.8 Hz), 7.73(2H, d, J=8.4 Hz), 7.56(2H, d, J=8.4 Hz), 7.44(2H, d, J=8.8 Hz), 6.49(1H, s), 5.88(1H, m), 5.35-5.20(2H, m), 4.30-4.10(4H, m), 4.00(2H, m), 2.65(3H, s), 1.93(3H, s), 1.31(3H, t, J=7.2 Hz).

Example 2 (r)

[0319] 390

[0320] TLC:Rf 0.46 (chloroform:methanol:acetic acid=10:2:1),

[0321] NMR (CD3OD): δ 8.18(2H, d, J=9.0 Hz), 7.93(2H, d, J=9.0 Hz), 7.82(2H, d, J=9.0 Hz), 7.80(1H, s), 7.52(2H, d, J=9.0 Hz), 4.66(1H, dd, J=8.5 Hz,4.0 Hz), 4.33(2H, q, J=7.0 Hz), 4.20(2H, q, J=7.0 Hz), 4.12(2H, q, J=7.0 Hz), 2.39(2H, t, J=7.0 Hz), 2.11-2.31(1H, m), 1.82-2.00(1H, m), 1.36(3H, t, J=7.0 Hz), 1.24(3H, t, J=7.0 Hz), 1.21(3H, t, J=7.0 Hz).

Example 2 (s)

[0322] 391

[0323] TLC:Rf 0.43 (chloroform:methanol:acetic acid=10:2:1),

[0324] NMR (CD3OD): δ 8.20 and 8.22(2H, d, J=8.0 Hz), 7.92(2H, d, J=9.0 Hz), 7.75-7.90(1.6H, m), 7.64(1H, d, J=8.0 Hz), 7.54(2H, d, J=9.0 Hz), 7.18 and 7.26(0.4H, m),5.54-5.72(0.4H, m), 5.10-5.31(2H, m), 4.17-4.40(6H, m), 3.98(2H, br), 1.08-1.38(6H, m).

Example 2 (t)

[0325] 392

[0326] TLC:Rf 0.15 (chloroform:acetic acid:H2O=3:1:1),

[0327] NMR (CD3OD): δ 8.23(2H, d, J=8 Hz), 7.93(2H, d, J=8 Hz), 7.58(2H, d, J=8 Hz), 7.53(2H, d, J=8 Hz), 6.80(1H, bs), 6.10-5.90(1H, b), 5.35-5.20(2H, m), 4.25-4.00(4H, m), 3.68-3.45(2H, m), 3.25-3.00(2H, m), 2.88(6H, s), 2.69(3H, s), 2.15(3H, s), 1.96(3H, s).

Example 2 (u)

[0328] 393

[0329] TLC:Rf 0.46 (chloroform:methanol:acetic acid=10:2:1),

[0330] NMR (CD3OD): δ 8.18(2H, d, J=9.0 Hz), 7.93(2H, d, J=9.0 Hz), 7.82(2H, d, J=9.0 Hz), 7.80(1H, s), 7.52(2H, d, J=9.0 Hz), 4.66(1H, dd, J=8.5 Hz,4.0 Hz), 4.33(2H, q, J=7.0 Hz), 4.20(2H, q, J=7.0 Hz), 4.12(2H, q, J=7.0 Hz), 2.39(2H, t, J=7.0 Hz), 2.11-2.31(1H, m), 1.82-2.00(1H, m), 1.36(3H, t, J=7.0 Hz), 1.24(3H, t, J=7.0 Hz), 1.21 (3H, t, J=7.0 Hz).

Example 2 (v)

[0331] 394

[0332] TLC:Rf 0.22 (chloroform:methanol:acetic acid=10:2:1),

[0333] NMR (CD3OD): δ 8.21(2H, d, J=8.0 Hz), 7.95(2H, d, J=8.0 Hz), 7.89(2H, d, J=8.0 Hz), 7.59(2H, d, J=8.0 z), 7.55(2H, d, J=8.0 Hz), 7.43(2H, d, J=8.0 Hz), 6.78(1H, s), 6.15-5.80(1H, m), 5.47-5.28(2H, m), 4.42(2H, s), 4.25(2H, d, J=5.0 Hz), 2.68(3H, S, CH3SO3H), 2.18(3H, s).

Example 2 (w)

[0334] 395

[0335] TLC:Rf 0.27 (chloroform:methanol:acetic acid=10:2:1),

[0336] NMR (CD3OD): δ 8.20(2H, d, J=8 Hz), 7.91(2H, d, J=8 Hz), 7.57(2H, d, J=8 Hz), 7.53(21, d, J=8 Hz), 6.73(1H, s), 5,8-6.0(1H, br), 5.2-5.35(2H, m), 4.8-4.9(1H, m), 4.0-4.3(8H, m), 2.12(3H, s), 1.91(3H, s)1.27(6H, t, J=7 Hz).

Example 2 (x)

[0337] 396

[0338] TLC:Rf 0.25 (chloroform:methanol:acetic acid=10:2:1),

[0339] NMR (CD3OD): δ 8.22(2H, d, J=8 Hz), 7.91(2H, d, J=8 Hz), 7.52 and 7.67(4H, d, J=8 Hz, rotamer), 6.65 and 6.78(1H, s, rotamer), 5.6-6.0(3H, br), 5.0-5.3(6H, m), 3.9-4.4(8H, m), 2.11 and 2.16(3H, s, rotamer), 1.92(3H, s).

Example 2 (y)

[0340] 397

[0341] TLC:Rf 0.41 (chloroform:methanol:acetic acid=20:2:1),

[0342] NMR (CD3OD): δ 8.22(2H, d, J=8.0 Hz), 7.94(2H, d, J=8.0 Hz), 7.55(4H, t, J=7.5 Hz), 6.71(1H, brs), 5.20-4.90(1H, m), 4.40-4.00(6H, m), 2.20-2.00(3H, m), 1.95-1.50(3H, m), 1.30(6H, t, J=7.5 Hz), 1.10-0.80(6H, m).

Example 2 (z)

[0343] 398

[0344] TLC:Rf 0.40 (chloroform:methanol:acetic acid=20:2:1),

[0345] NMR (CD3OD): δ 8.21(2H, d, J=8.5 Hz), 7.95(2H, d, J=8.5 Hz), 7.57(4H, t, J=8.0 Hz), 6.62(1H, s), 4.15(2H, q, J=7.0 Hz), 3.80-3.60(2H, m), 3.55-3.38(2H, m), 2.68(2H, t, J=7.5 Hz), 2.12(3H, s), 1.70-1.40(3H, m), 1.27(3H, t, J=7.5 Hz), 1.10-0.70(6H, m).

Example 2 (aa)

[0346] 399

[0347] TLC:Rf 0.55 (chloroform:methanol:acetic acid=10:2:1),

[0348] NMR (CD3OD): δ 8.23(2H, d, J=8 Hz), 7.93(2H, d, J=8 Hz), 7.57(2H, d, J=8 Hz), 7.54(2H, d, J=8 Hz), 6.60(1H, s), 3.92-3.50(3H, m), 2.70-2.55(2H, m), 2.13 and 2.11(3H, s), 1.93-1.00(10H, m).

Example 2 (bb)

[0349] 400

[0350] TLC:Rf 0.41 (chloroform:methanol:acetic acid=10:2:1),

[0351] NMR (CD3OD): δ 8.21(2H, d, J=8 Hz), 7.92(2H, d, J=8 Hz), 7.65-7.50(4H, m), 6.72 and 6.65(1H, s, rotamer), 4.2-4.1(4H, m), 3.8-3.6(2H, br), 3.6-3.5(2H, br), 3.34(3H, s), 2.17(3H, s), 1.91(AcOH), 1.35-1.15(3H, br).

Example 2 (cc)

[0352] 401

[0353] TLC:Rf 0.30 (chloroform:methanol:acetic acid=10:2:1),

[0354] NMR (CD3OD): δ 8.21(2H, d, J=8 Hz), 7.92(2H, d, J=8 Hz), 7.60-7.45(4H, m), 6.73 and 6.65(1H, s, rotamer), 4.5-4.3(1H, m), 4.3-4.0(2H, br), 4.0-3.7(3H, m), 3.7-3.5(1H, br), 2.70(3H, s), 2.17 and 2.10(3H, s, rotamer), 2.2-1.8(3H, m), 1.8-1.4(1H, m).

Example 2 (dd)

[0355] 402

[0356] TLC:Rf 0.10 (ethyl acetate:acetic acid:H2O=3:1:1),

[0357] NMR (CD3OD): δ 8.22(2H, d, J=8 Hz), 7.92(2H, d, J=8 Hz), 7.7-7.4(4H, m), 6.70(1H, s), 4.5-4.0(3H, br), 3.6-3.4(2H, m), 3.2-3.0(2H, m), 2.3-1.9(7H, br).

Example 2 (ee)

[0358] 403

[0359] TLC:Rf 0.43 (chloroform:methanol:acetic acid=3:1:1),

[0360] NMR (CD3OD): δ 9.20(1H, br. s), 8.70(1H, br. s), 8.05-7.95(4H, m), 7.85(2H, d, J=9 Hz), 7.75(2H, J=8 Hz), 6.75(1H,m), 5.95(1H, m), 5,30(2H, m), 4.20(4H, m), 2.75(3H, s, CH3SO3H), 2.20(3H, s).

Example 2 (ff)

[0361] 404

[0362] TLC:Rf 0.40 (chloroform:methanol:acetic acid=10:2:1),

[0363] NMR (CDCl3): δ 8.02(1H, d, J=9 Hz), 7.90(1H, d, J=9 Hz), 7.64(1H, s), 7.50(1H, d, J=9 Hz), 7.40-7.00(1411, m), 6.95-6.80(2H, m), 6.80-6.72(1H, m), 6.48(1H, d, J=9 Hz), 4.00-3.80(1H, m), 3.88(3H, s), 3.70-3.30,(2H, m), 3.10-2.90(1H, m), 2.90-2.70(2H, m), 2.70-2.30(2H, m), 2.30-2.00(2H, m), 1.00-1.24(1H, m).

Reference Example 3

[0364] 2-(N-Benzyl-N-methylamino)-2-(4-t-butoxycarbonylphenylmethylimino)acetic Acid Ethyl Ester. 405

[0365] To a solution of 2-(N-benzyl-N-methylamino)-2-thioxoacetic acid ethyl ester (4.98 g) in dichloromethane under cooling with ice, was added dropwise BF4—Et3O (72 ml). The reaction solution was stirred for 30 min at room temperature and extracted with dichloromethane. The extract was evaporated. The resulting residue was purified by silica gel column chromatography to obtain the title compound having the following the physical data.

[0366] TLC:Rf 0.45 (hexane:ethyl acetate=3:1).

Reference Example 4

[0367] 2-(N-Benzyl-N-methylamino)-2-(4-carboxyphenylmethylimino)acetic Acid Ethyl Ester 406

[0368] To a solution of the compound prepared in Reference Example 3 (3.77 g) in anisole (10 ml) under cooling with ice bath, was added trifluoroacetic acid (20 ml) and stirred for two hours at room temperature. The reaction solution was evaporated, neutralizied by adding 1N aqueous solution of sodium hydroxide, and extracted with ethyl acetate. The extract was evaporated. The resulting residue was purified by silica gel column chromatography to obtain the title compound (1.87 g) having the following physical data.

[0369] TLC:Rf 0.36 (hexane:ethyl acetate=1:2).

Example 3

[0370] 2-[4-(4-Amidinophenoxycarbonyl)phenylmethylimino]-2-(N-benzyl-N-methylamino)acetic Acid Ethyl Ester Hydrochroride 407

[0371] By the same procedure as Example 2, the title compound having the following physical data was obtained.

[0372] TLC:Rf 0.34 (chloroform:methanol:acetic acid=10:2:1),

[0373] NMR (CD3OD): δ 1.26(3H, t, J=7.0 Hz), 2.88(3H, s), 4.36(2H, q, J=7.0 Hz), 4.49(2H, s), 4.50(2H, s), 7.27-7.35(5H, m), 7.48(2H, d, J=9.0 Hz), 7.52(2H, d, J=9.0 Hz), 7.92(2H, d, J=9.0 Hz), 8.12(21H, d, J=9.0 Hz).

Reference Example 5

[0374] Ethyl 1-(3-phenylpropyl)-1-(4-benzyloxycarbonylphenylmethyl)phosphinate. 408

[0375] A solution of ethyl phenylpropylphosphinate (1.2 g) and triethylamine (2.4 ml) in chloroform (30 ml) was cooled to 0° C., and a solution of trimethylsilylchloride (1.46 ml) and 4-bromomethylbenzoic acid benzyl ester (1.75 g) in chloroform (10 ml) was added thereof, and stirred at room temperature for 1.5 day. To the reaction mixture was added ice water and extracted with ethyl acetate. Organic layer was washed with water and a saturated aqueous solution of sodium chloride, successively evaporated. The residue was purified by silica gel column chromatography to give the title compound (900 mg).

Reference Example 6

[0376] Ethyl 1-(3-phenylpropyl)-1-(4-carboxyphenylmethyl)phosphinate 409

[0377] A mixture of the compound prepared in Reference Example 5 (900 mg), palladium carbon (180 mg, 10%) and ethanol (20 ml) was stirred for two hours under an atmosphere of hydrogen at room temperature. The reaction mixture was filtered. The filtrate was evaporated and the title compound (815mg) was obtained.

Example 4

[0378] Ethyl 1-(4-amidinophenoxycarbonylphenylmethyl)-1-(3-phenylpropyl)phosphinate acetate 410

[0379] By the same procedure as Reference Example 5,6 and Example 2, the title compound (805 mg) having the following physical data was obtained.

[0380] TLC:Rf 0.62 (chloroform:methanol:acetic acid=10:2:1),

[0381] NMR (CD3OD): δ 8.10(2H, d, J=8 Hz), 7.95(2H, d, J=9 Hz), 7.55(2H, d, J=9 Hz), 7.60-7.40(2H, m), 7.30-7.10(3H, m), 7.20(2H, d, J=8 Hz), 4.00(2H, m), 3.40(2H, d, J=24 Hz), 2.70(2H, t, J=6.5 Hz), 2.00-1.60(4H, m), 1.30(3H, t,J=7.5 Hz).

Example 4(a)

[0382] 411

[0383] By the same procedure as Example 4, the compound having the following physical data was obtained.

[0384] TLC:Rf 0.60 (chloroform:methanol:acetic acid=10:2:1),

[0385] NMR (CD3OD): δ 1.36(6H, t, J=7.0 Hz), 4.15(4H, quin, J=7.0 Hz), 6.68(1H, t, J=18.0 Hz), 7.54(2H, d, J=9.0 Hz), 7.56(1H, dd, J=23.0 Hz,18.0 Hz), 7.82(2H, d, J=9.0 Hz), 7.93(2H, d, J=9.0 Hz), 8.22(2H, d, J=9.0 Hz).

Reference Example 7

[0386] 4-Phenylpiperidine-1-ylmethylbenzoic Acid Methyl Ester 412

[0387] A solution of 4-formylbenzoic acid (3.5 g) and 4-phenylpiperidine (6.9 g) in methanol (35 ml) was stirred for one hour at room temperature. After the solution was cooled with ice bath, sodium borohydride (1.63 g) was added and the reaction solution was stirred. After the reaction finished, the reaction solution was poured into ice water and extracted with ethyl acetate. The organic layer was washed with water and a saturated aqueous solution of sodium chloride, successively, dried over and evaporated. The residue was washed with methanol to obtain the title compound (4.70 g).

Reference Example 8

[0388] 4-(4-Phenylpiperidine-1-ylmethyl)benzoic Acid 413

[0389] A solution of the compound prepared in Reference Example 7 (4.8 g) in dioxane (50 ml) was cooled with ice bath and 2N aqueous solution of sodium hydroxide (10 ml) was added thereof and stirred at 60° C. for two hours. The reaction mixture was cooled with ice bath and neutralized by adding 2N hydrochloric acid. Depositing solid was fittered and washed with water, ether successively, dried over. The title compound (4.29 g) was obtained.

Example 5

[0390] 4-(4-Phenylpiperidine-1-ylmethyl)benzoic Acid Amidinophenol Ester 2 Hydrochloride 414

[0391] By the same procedure as Example 2, the title compound having the following physical data was obtained.

[0392] TLC:Rf 0.33 (chloroform:methanol:acetic acid=5:1:1),

[0393] NMR (CD3OD): δ 8.32(2H, d, J=8.0 Hz), 7.95(2H, d, J-8.8 Hz), 7.88(2H, d, J=8.0 Hz), 7.55(2H, d, J=8.8 Hz), 7.28(5H, m), 4.52(2H, s), 3.62(2H, br.d), 3.25(2H, br.d), 2.94(1H, m), 2.12(4H, m).

Example 5(a)-5(b)

[0394] By the same procedure as Reference Example 7,8 and Example 5, the compounds having the following physical data were obtained.

Example 5 (a)

[0395] 415

[0396] TLC:Rf 0.3 (chloroform:methanol:acetic acid=50:10:1),

[0397] NMR (CD3OD): δ 8.20(2H, d, J=8.0 Hz), 7.95(2H, d, J=8.0 Hz), 7.81(1H, d, J=2.0 Hz), 7.79(1H, d, J=2.0 Hz), 7.69(5H, brs), 7.55(2H, d, J=8.5 Hz), 7.39(2H, d, J=8.5 Hz), 5.63(2H, s), 2.72(6H, s).

Example 5 (b)

[0398] 416

[0399] TLC:Rf 0.48 (chloroform:methanol:acetic acid=10:1:1),

[0400] NMR (CD3OD+CDCl3): δ 8.05(2H, d, J=8.4 Hz), 7.89(2H, d, J=8.8 Hz), 7.71(1H, d, J=8.0 Hz), 7.46(2H, d, J=8.8 Hz), 7.40(1H, s), 7.37-7.30(2H, m), 7.17(1H, d, J=8.0 Hz), 7.16(2H, d, J=8.4 Hz), 5.95(2H, s), 4.30(2H, q, J=7.4 Hz), 2.73(3H, s), 1.33(3H, t, J=7.4 Hz).

Reference Example 9

[0401] 4-(N-Benzyl-N-ethoxycarbonylaminomethyl)benzoic Acid Benzyl Ester 417

[0402] A solution of 4-(N-benzylaminomethyl)benzoic acid benzyl ester (5.21 g) and bromoacetic acid benzyl ester (1.7 ml) in DMF (10 ml) was stirred for two hours at 80° C. and ice water was added thereto. The reaction solution was extracted with ethyl acetate. The organic layer was washed with a saturated aqueous solution of sodium hydrogen carbonate, water and a saturated aqueous solution of sodium chloride, successively. The organic layer was dried over and evaporated. The residue was purified by silica gel column chromatography to obtain the title compound (2.26 g).

Reference Example 10

[0403] 4-(N-Benzyl-N-ethoxycarbonylaminomethyl)benzoic Acid Hydrochloride 418

[0404] A mixture solution of the compound prepared in Reference Example 9 (2.26 g), methanesufonic acid (10.5 ml), and anisole (25 ml) was stirred for one hour at room temperature. To the reaction solution was added ice water and extracted with chloroform. The organic layer was washed with water, a saturated aqueous solution of sodium chloride, dried over and evaporated. The residue was purified by silica gel column chromatography to obtain amine. 4N hydrochloric acid-dioxane was added to the amine and the mixture was evaporated to obtain the title compound (1.76 g).

Example 6

[0405] N-(4-(4-Amidino-phenoxycarbonyl)phenylmethyl)-N-benzylaminoacetic Acid Ethyl Ester 2 Hydrochroride 419

[0406] By the same prodedure as Example 2, the title compound having the following physical data was obtained.

[0407] TLC:Rf 0.42 (chloroform:methanol:acetic acid=10:2:1),

[0408] NMR (CD3OD): δ 8.25(2H, d, J=8 Hz), 7.90(2H, d, J=8 Hz), 7.60(2H, d, J=8 Hz), 7.50(2H, d, J=8 Hz), 7.40-7.20(5H, m), 4.15(2H, q, J=7 Hz), 3.90(2H, s), 3.80(2H, s), 3.30(2H, s), 1.25(3H, t, J=7 Hz).

Formulation Example I
The following components were admixed in a conventional manner and
punched out to obtain 100 tables, each containing 100 mg of active
ingredient.
	Compound number 1	10	g
	Cellulose calcium glycolate (disintegrating agent)	0.2	g
	Magnesium stearate (Lubricating agent)	0.1	g
	Microcrystaline cellulose	1.7	g
Formulation Example 2
The following components were admixed conventional method and
punched out to obtain 100 tables each containing 100 mg of active
ingredient.
	Compound number 2	1	g
	Cellulose calcium glycolate (disintegrating agent)	0.2	g
	Magnesium stearate (Lubricating agent)	0.1	g
	Microcrystaline cellulose	1.7	g
Formulation Example 3
The following components were admixed in conventional manner. The
solution was sterilized conventional manner, placed 5 ml portions into 10
ml ampoules and obtained 100 ampoules each containing 10 mg of the
active ingredient.
	Compound number 1	1	g
	Citric acid	0.2	g
	distilled water	500	ml
Formulation Example 4
The following components were admixed in conventional manner. The
solution was sterilized in conventional manner, placed 5 ml portions into
10 ml ampules to obtain 100 ampoules, each containing 10 mg of the
active ingredient.
	Compound number 2	1	g
	Citric acid	0.2	g
	distilled water	500	ml

[0409]

TABLE 1
420
Preferable groups as R
421 422
423 424
425 426
427 428
429 430
431 432
433 434
435 436
437 438
439 440
441

[0410]

TABLE 2
442
Preferable groups as R
443 444
445 446
447 448
449 450
451 452
453 454
455 456
457 458
459 460
461 462
463

[0411]

TABLE 3
464
Preferable groups as R
465 466
467 468
469 470
471 472
473 474
475 476
477 478
479 480
481 482
483 484
485

[0412]

TABLE 4
486
Preferable groups as R
487 488
489 490
491 492
493 494
495 496
497 498
499 500
501 502
503 504
505 506
507

[0413]

TABLE 5
508
Preferable groups as R
509 510
511 512
513 514
515 516
517 518
519 520
521 522
523 524
525 526
527 528
529

[0414]

TABLE 6
530
Preferable groups as R
531 532
533 534
535 536
537 538
539 540
541 542
543 544
545 546
547 548
549 550
551

[0415]

TABLE 7
552
Preferable groups as R
553 554
555 556
557 558
559 560
561 562
563 564
565 566
567 568
569 570
571 572
573

[0416]

TABLE 8
574
Preferable groups as R
575 576
577 578
579 580
581 582
583 584
585 586
587 588
589 590
591 592
593 594
595

[0417]

TABLE 9
596
Preferable groups as R
597 598
599 600
601 602
603 604
605 606
607 608
609 610
611 612
613 614
615 616
617

[0418]

TABLE 10
618
Preferable groups as R
619 620
621 622
623 624
625 626
627 628
629 630
631 632
633 634
635 636
637 638
639

[0419]

TABLE 11
640
Preferable groups as R
641 642
643 644
645 646
647 648
649 650
651 652
653 654
655 656
657 658
659 660
661

[0420]

TABLE 12
662
Preferable groups as R
663 664
665 666
667 668
669 670
671 672
673 674
675 676
677 678
679 680
681 682
683

[0421]

TABLE 13
684
Preferable groups as R
685 686
687 688
689 690
691 692
693 694
695 696
697 698
699 700
701 702
703 704
705

[0422]

TABLE 14
706
Preferable groups as R
707 708
709 710
711 712
713 714
715 716
717 718
719 720
721 722
723 724
725 726
727

[0423]

TABLE 15
728
Preferable groups as R
729	730	731	732
733	734
735	736	737
738	739
740

[0424]

TABLE 16
741
Preferable groups as R
742	743	744	745
746	747	748
749	750
751	752
753
754	755	756	757
758	759	760
761	762

[0425] Pharmaceutical compositions of the present invention can be prepared using one active ingredient or two or more active ingredients.

[0426] Salts and Acid-additon Salts

[0427] Compounds of the formulae (IA) and (IB) of the present invention may be converted into the corresponding salts and acid-addition salts by known methods. Nontoxic and water-soluble salts are preferred.

[0428] Suitable salts include the salts of alkali metals (sodium, potassium etc.), alkaline-earth metal (calcium, magnesium etc.), ammonium salts, salts of pharmacoligically acceptable organic amines (tetramethyl ammonium, triethylamine, methylamine, dimethylamine, cyclopentylamine, benzylamine, phenetylamine, piperidine, monoethanolamine, diethanolamine, tris (hydroxymethyl)aminomethane, lysine, arginine, N-methyl-D-gulcane etc).

[0429] Suitable acid-addition salts include the salts with inorganic acids such as hydrochloric acid, and the salts with organic acids such as acetic acid, trifluoroacetic acid, lactic acid, tartaric acid, oxalic acid, fumaric acid, maleic acid, citric acid, benzoic acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, toluenesulfonic acid, isethionic acid, glucuronic acid and gluconic acid. Preferred salts include the salts with acids such as hydrochloric acid, methanesulfonic acid, acetic acid and trifluoroacetic acid.

[0430] Preparation of Compounds

[0431] The compounds of the formula (IA) may be prepared by methods known per se, as defined in published applications EP-A-588655 and EP-A-656349. The formula (1B) compounds of the present invention may be prepared by forming an ester or amide bond between a compound of the formula (II): 763

[0432] (wherein the various symbols have the same meanings as hereinbefore defined) with a compound of the formula (III): 764

[0433] (wherein the various symbols have the same meanings as hereinbefore defined). The esterification reaction and the reaction to form an amide are known and can be carried out by known method, for example:

[0434] (1) using an acid halide,

[0435] (2) using a mixed acid anhydride or

[0436] (3) using a condensing agent.

[0437] Esterification can be carried out, for example, as follows:

[0438] (1) the method using an acid halide may be carried out, for example, by reacting a carboxylic acid with an acid halide (e.g., oxalyl chloride, thionyl chloride etc.) in an inert organic solvent (e.g., chloroform, methylene chloride, diethyl ether, tetrahydrofuran etc.) or without a solvent at from −20° C. to the reflux temperature of the solvent, and then by reacting the acid halide obtained with a corresponding alcohol in the presence of a tertiary amine (e.g., pyridine, triethylamine, diethylaniline, diethylaminopyridine etc.) in an inert organic solvent (e.g., chloroform, methylene chloride, diethyl ether, tetrahydrofuran etc.) at a temperature of from 0° C. to 40° C.;

[0439] (2) the method using a mixed acid anhydride may be carried out, for example, by reacting a carboxylic acid and an acid halide (e.g., pivaloyl chloride, tosyl chloride, mesyl chloride etc.) or an acid derivative (e.g., ethyl chloroformate, isobutyl chloroformate etc.) in the presence of a tertiary amine (e.g., pyridine, triethyamine, dimethylaniline, dimethylaminopyridine etc.) in an inert organic solvent (e.g., chloroform, methylene chloride, diethyl ether, tetrahydrofuran etc.) or without a solvent at a temperature of from 0° C. to 40° C., and then by reacting the mixture of acid anhydride obtained with a corresponding alcohol in an inert organic solvent (e.g., chloroform, methylene chloride, diethyl ether, tetrahydrofuran etc.), at a temperature of from 0° C. to 40° C.; and

[0440] (3) the method using a condensing agent (e.g., 1,3-dicyclohexylcarbodiimide (DCC), 1-ethyl-3-[(dimethylamino)propyl] cabodiimide (EDC), 2-chloro-1-methypyridinium iodide etc.) may be carried out, for example, by reacting a carboxylic acid with a corresponding alcohol using a condensing agent in the presence or absence of a tertiary amine (e.g., pyridine, triethylamine, dimethylaniline, dimethylaminopyridine etc.) in an inert organic solvent (e.g., chloroform, methylene chloride, dimethyl formamide, diethyl ether etc.) or without a solvent at a temperature of from 0° C. to 40° C.

[0441] The formation of an amide may be accomplished by the same reactions as described above, except the corresponding alcohol is replaced by a corresponding amine.

[0442] The reactions (1), (2) and (3) hereinbefore described may be preferably carried out in an atmosphere of inert gas (e.g., argon, nitrogen etc.) under anhydrous conditions.

[0443] The compounds of the formula (III) may be prepared by the series of reactions depicted in the following Scheme A. 765

[0444] In the Scheme A,

[0445] RP is t-butyl or benzyloxycarbonyl,

[0446] X10, X20 and X30 each independently, is halogen,

[0447] Ms is methaneosulfonic acid,

[0448] A00 is bond, C1-3 alkylene, oxy-(C1-3) alkylene, thio-(C1-3)alkylene, C2-7 alkenylene, C2-7 alkenylene substituted by carboxy or C1-4 alkoxycarbonyl, and the other symbols have the same meaning as hereinbefore described.

[0449] The reactions in the scheme hereinbefore depicted may be carried out by methods known per se. The compounds of the formulae (II), (IV), (V) and (VI) used as starting materials in this scheme are known per se or may be easily prepared by methods known per se.

[0450] Other starting materials and each of the reagents are known per se or may be prepared by known methods.

[0451] In each reaction in the present specification, products may be purified in a conventional manner. For example, purification may be carried out by distillation at atmospheric or reduced pressure, high performance liquid chromatography, thin layer chromatography or column chromatography using silica gel or magnesium silicate, washing or recrystallization. Purification may be carried out after each reaction, or after a series of reactions.

[0452] Physiological Effects

[0453] As mentioned above, it is understood that LTB4 antagonist is useful as an anti-inflammatory and anti-allergic agent.

[0454] Therefore, compounds of the present invention of formulas (IA) and (IB), having LTB4 antagonistic activity, may be used for the treatment of an animal, preferably a human, as an anti-inflammatory and anti-allergic agent.

[0455] It is known that an LTB4 antagonist is also useful for the prevention and/or treatment of various diseases in animals, including humans. These diseases include rheumatoid arthritis, inflammatory bowel diseases, psoriasis, nonsteroidal anti-inflammatory agent-induced stomach diseases, adult respiratory distress syndrome, cardiac infarction, allergic rhinitis, hemodialysis-induced neutropenia and anaphase asthma.

[0456] The compounds of the formula (IB) also have inhibitory activity on phospholipase and inhibitory activity on trypsin in animals, including humans. Therefore compounds of formula (IB) are useful for the prevention and/or the treatment of various inflammatory, allergic diseases, disseminated intravascular coagulation, pancreatitis, severity in pancreatitis and multiple organ failure in animals, preferably humans.

[0457] Toxicity

[0458] It is confirmed that the toxicity of the active ingredients and non-toxic salts thereof and non-toxic acid addition salts thereof in the present invention is very weak. For example, LD50 of Compound 1 was 117mg/kg when administered intravenously to male mice. Accordingly, the active substances in the present invention may be considered to be sufficiently safe and suitable for pharmaceutical use.

[0459] For the purpose hereinbefore described, the active ingredient in the present invention and non-toxic salts thereof and non-toxic acid addition salts thereof may be normally administered systemically or partially, usually by oral or parenteral administration.

[0460] The doses to be administered are determined depending upon age, weight, symptom, the desired therapeutic effect, the route of administration, and the duration of the treatment, etc. In the human adult, the doses per person per dose are generally between 1 mg and 1000 mg, by oral administration, up to several times per day, or between 100 μg and 100 mg, by parenteral administration (preferably, intravenously) up to several times per day. As mentioned above, the doses to be used depend upon various conditions. Therefore, there are cases in which doses lower than or greater than the ranges specified above may be used.

[0461] Compounds of the present invention are administered in the form of solid compositions, liquid compositions or other compositions for oral administration, and as injections, liniments or suppositories, etc., for parenteral administration.

[0462] Solid compositions for oral administration include compressed tablets, pills, capsules, dispersible powders, and granules.

[0463] In such compositions, at least one of the active compounds is admixed with at least one inert diluent (such as lactose, mannitol, glucose, hydroxypropyl cellulose, microcrystalline cellulose, starch, polyvinylpyrrolidone, magnesium metasilicate aluminate, etc.).

[0464] These compositions may also comprise, as in normal practice, additional substances other than inert diluents: e.g., lubricating agents (such as magnesium stearate, etc.), disintegrating agents (such as cellulose calcium glycolate, etc.), assisting agents for dissolving (such as arginine, glutamic acid, asparaginic acid, etc.) and stabilizers (human serum albumin, lactose, etc.).

[0465] The tablets or pills may, if desired, be coated with a film of gastric or enteric material (such as sugar, gelatin, hydroxypropyl cellulose, hydroxypropylmethyl cellulose phthalate, etc.).

[0466] Capsules include hard capsules and soft capsules.

[0467] Liquid compositions for oral administration include solutions, emulsions, suspensions, syrups and elixirs.

[0468] These liquid compositions may comprise inert diluents commonly used in the art (purified water, ethanol, etc.).

[0469] Besides inert diluents, such compositions may also comprise adjuvants (such as wetting agents, suspending agents, etc.), sweetening agents, flavoring agents and preserving agents.

[0470] Other compositions for oral administration include spray compositions, which may be prepared by known methods and which comprise one or more of the active compound(s). Spray compositions may comprise additional substances other than inert diluents: e.g. stabilizing agents (sodium sulfate, etc.), isotonic stabilizing agents (sodium chloride, sodium citrate, citric acid, etc.). For preparation of such spray compositions, for example, the method described in the U.S. Pat. No. 2,868,691 or No. 3,095,355 may be used.

[0471] Injections for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions and emulsions.

[0472] In such compositions, one or more of active compound(s) is or are admixed with at least one of inert aqueous diluent(s) (distilled water for injection, physiological salt solution, etc.) or inert non-aqueous diluent(s) (propylene glycol, polyethylene glycol, olive oil, ethanol, POLYSORBATE80 (registered trademark) etc.).

[0473] Injections may comprise furthermore assisting agents such as preserving agents, wetting agents, emulsifying agents, dispersing agents, stabilizing agents (such as human serum albumine, lactose, etc.) and assisting agents for dissolving (arginine, glutamic acid, asparaginic acid, polyvinylpyrrolidone, etc.).

[0474] Usually, they may be sterilized by filtration (a bacteria-retaining filter etc), by incorporation of sterilizing agents in the compositions or by irradiation, or after treated, they may also manufactured in the form of sterile solid compositions, for example, by freeze-drying, which may be dissolved in sterile water or some other sterile diluent(s) for injection immediately before used, and which may be used.

Example

[0475] The following Reference Examples and Examples illustrarte the present invention.

[0476] The solvents in parentheses show the developing or eluting solvents used in chromatographic separations and the solvent ratios used are by volume.

Example 1 (A)

[0477] Binding Inhibition Against 3H-LTB4 on the Human Polymorphonuclear Leukocyte (PMN)

[0478] 0.049 ml Hanks balanced salt solution (HBSS), 0.001 ml test compound and 0.05 ml 3H-LTB4 (4nM) were added to polypropylene tubes and mixed. The reaction was started by addition of a thoroughly mixed PMN cell suspension (1.6×106 cells), followed by incubation at 0° C. for 20 min. The reaction was terminated by the addition of ice-cold HBSS (2.5 ml). PMNs were harvested by vacuum filtration through Whatman GF/C glass fiber filters on a Brandel cell harvester (BRANDEL, M-24R). The filters were then washed 2 times to remove free 3H-LTB4 with 2.5 ml of the ice-cold PBS (−) solution. The filters were transferred to each vial, and equilibrated after adding 8 ml ACS II cocktail (Amersham). The radioactivity was measured by liquid scintillation counter (Aloka, LSC-5100).

[0479] Specific binding of 3H-LTB4 to the LTB4 receptor was defined as total binding minus nonspecific binding. Nonspecific binding was the amount of 3H-LTB4 binding in the presence of 1.5 μM LTB4 instead of the test compound. The inhibitory effect of test compound was calculated from the following equation.

The percentage of inhibition (%)=100−(B1/B0×100)

[0480] B1: Specific 3H-LTB4 binding in presence of test compound

[0481] B0: Specific 3H-LTB4 binding in absence of test compound

[0482] Results

[0483] The results are shown in the following Table 17.

TABLE 17
	European Patent Publication
	No. 588655	binding activity
Compound No.	Compound (Example No.)	(%)
1	1 (i)	91.5
2	1 (m)	76.6
3	1 (p)	75.0
4	1 (aa)	63.7
5	1 (ii)	94.3
6	1 (pp)	71.6
7	1 (qq)	78.0
8	1 (hhh)	82.7
9	1 (lll)	91.6
10	1 (mmm)	86.5
11	2 (g)	76.8
12	2 (p)	95.2
13	2 (u)	100.2
14	2 (w)	96.5
15	2 (cc)	89.1
16	2 (gg)	83.6
17	2 (kk)	93.9
18	3 (f)	87.0
19	4	74.0
20	4 (a)	83.5
21	5 (r)	90.8
22	5 (w)	89.7
23	5 (ff)	78.0
24	European Patent Publication	61.2
	No. 656349
	Example 1 (b)

[0484] The structure of compounds used in the present invention are shown below. Compound No. 1 766

Example 1 (B)

[0485] The compounds of the formula (IB), of the present invention have an antagonistic activity on LTB4 The results which are measured by method as hereinbefore described in Example 1 (A), are shown the following Table 18.

TABLE 18
                       binding activity
Compound (Example No.) (%)
2                      79.7
2 (a)                  92.0
2 (b)                  97.9
2 (c)                  103.2
2 (d)                  99.3
2 (e)                  94.5
2 (f)                  91.8
2 (g)                  89.6
2 (h)                  85.4
2 (i)                  69.6
2 (j)                  55.4
2 (k)                  97.7
2 (l)                  81.0
2 (m)                  89.2
2 (n)                  82.8
2 (o)                  85.8
2 (p)                  95.2
2 (q)                  98.0
2 (r)                  80.1
2 (s)                  83.0
2 (t)                  51.5
2 (u)                  67.6
2 (v)                  92.0
2 (w)                  76.7
2 (x)                  94.1
2 (y)                  85.5
2 (z)                  92.8
2 (aa)                 94.4
2 (bb)                 87.3
2 (cc)                 76.7
2 (dd)                 50.8
2 (ee)                 65.3
2 (ff)                 82.4
3                      96.8
4                      73.1
4 (a)                  52.0
5                      89.7
5 (a)                  62.5
5 (b)                  90.2
6                      67.8

Example 1 (C)

[0486] Inhibitory Activity on Phospholipase A2 and on Trypsin

[0487] It has been confirmed that compounds of formula (IB) of the present invention have inhibitory activities on phospholipaseA2 (PLA2) and on trypsin.

[0488] For example, in laboratory tests the following results were obtained.

[0489] Method

[0490] (1) Inhibitory Activity on PLA2

[0491] A reaction solution including 50 mM tris-HCl buffer (pH7.5, 874 μl; containing 100 mM sodium chloride, 1 mM EDTA), 1M calciumchloride (6 μl), 1% bovine serum albumin (10 μl) and 2.5 mM 10PY-PC (10 μl), was prepared. To the solution were added a test compound in various concentration or water (50 μl), and a solution of 10 mU/ml PLA2 (derived from hog pancreas) (501 μl). The appearance of fluorescence was measured (Ex=345 nm, Em=396 nm). Percentage (%) of the strength of fluorescence in the presence of a test compound was calculated when the strength of that in the absence thereof was regarded as 100%, and therefrom IC50 value was calculated. The results are shown in the following Table19.

[0492] (2) Inhibitory Activity on Trypsin

[0493] To a mixture of a 0.2 M HEPES•sodium hydroxide buffer solution (pH 8.0, 100 μl) and distilled water (640 μl), were added a test compound in various concentration or water (10 μl), and a solution of 80 mU/ml trypsin (derived from bovine pancreas) (50 μl) and then the mixture was preincubated for one minute at 30° C. To the solution thus obtained was added 2.5 mM BAPNA (200 μl) and the mixture was incubated at 30° C. The absorbance at 405 nm was measured. Percentage (%) of the absorbance in the presence of a test compound was calculated when the absorbance in the absence thereof was regarded as 100%, and therefrom IC50 value was calculated. The results are shown in the following Table 19.

	TABLE 19
		inhibitory activity	inhibitory activity
	Compound	on PLA2	on trypsin
	(Example No.)	IC50 (μM)	IC50 (μM)
	2	—	0.19
	2(a)	2.6	0.4
	2(b)	3.8	0.56
	2(c)	8.1	0.26
	2(d)	8.7	0.14
	2(e)	8.5	0.34
	2(f)	70	0.10
	2(g)	53	0.16
	2(h)	11	0.15
	2(i)	59	0.14
	2(j)	—	0.12
	2(k)	20	0.10
	2(l)	94	0.12
	2(m)	18	0.17
	2(n)	10	0.16
	2(o)	12	0.14
	2(p)	29	0.13
	2(q)	34	0.16
	2(r)	46	0.16
	2(s)	44	0.16
	3	4.7	0.12
	4	41	0.16
	4(a)	—	0.14
	5	—	0.13
	5(a)	—	0.15
	6	4.5	0.17

[0494] In the methods hereinbefore described,

[0495] 10PY-PC represents 3′-palmitoyl-2-(1-pyrenedecanoyl)-L-α-phosphatidylcholine,

[0496] HEPES represents 4-2-hydroxyethyl)-1-piperazineethanesulfonic acid, and BAPNA represents α-N-benzoyl-DL-arginine-p-nitroanilide hydrochloride.

Claims

1. A new amidinophenol derivative of formula (IB):

2. A compound according to claim 1, wherein R is

3. A compound according to claim 1, wherein R is

4. A compound according to claim 1, wherein R is

5. A compound according to claim 1, wherein R is

6. A compound according to claim 1, wherein

7. A compound according to claim 1, wherein

8. A compound according to claim 1, wherein R50, R60 and R70 each independently, is (i) hydrogen, (ii) C1-8 alkyl, (iii) C2-8 alkenyl (iv)-COOR110, (v) —(C1-8 alkylene)-COOR110, (vi) —(C2-8 alkenylene)-COOR110, (vii) C4-7 cycloalkyl, (x) phenyl, (xi) C1-8 alkyl substituted by one or two phenyl, (xii) —(C1-4 alkylene)-O-benzoyl, (xiii) —(C1-4 alkylene)-CONH—(C1-4 alkylene)-NR120R130, (xiv) —(C1-4 alkylene)-COO—(C1-4 alkylene)-NR120R130, (xv) —(C1-4 alkylene)-OCO-amidinophenyl, (xvi) —(C1-4 alkylene)-CONH—(C1-4 alkyl substituted by one or two COOR110), (xvii) —(C1-4 alkylene)-CONR120R130, or (xviii) (C1-4) alkoxy (C1-4) alkyl in which the various symbols are defined in claim 1.

9. A compound according to claim 1, wherein R50, R60 and R70 each independently, is (viii) —(C1-4 alkylene)-(4-7 membered hetero ring containing one oxygen).

10. A compound according to claim 1, wherein R50, R60 and R70 each independently, is (ix) —(C1-4 alkylene)-(4-7 membered hetero ring containing one nitrogen).

11. A compound according to claim 1, which is 4-(4-amidinophenoxycarbonyl)phenoxyacetic acid N-2-propenyl-N-ethoxycarbonylmethylamide, 4-(6-amidino-7,8-dihydro-2-naphthyloxycarbonyl)benzoic acid N-phenyl-N-phenylmethylamide, 4-(6-amidino-7,8-dihydro-2-naphthyloxycarbonyl)benzoic acid N-phenyl-N-benzyloxycarbonylmethylamide, 4-(6-amidino-7,8-dihydro-2-naphthyloxycarbonyl)benzoic acid N-phenyl-N-ethoxycarbonylmethylamide, 4-[4-(2-amidinoethenyl)phenoxycarbonyl]benzoic acid N-phenyl-N-ethoxycarbonylmethylamide, 4-(4-amidinophenoxycarbonyl)-α-methylcinnamic acid N-(1-(S)-ethoxycarbonyl-2-benzoyloxyethylamide, 4-[2-(4-amidinophenoxycarbonyl)ethenyl]benzoic acid N-1-(S), 3-bis(ethoxycarbonyl)propylamide, 4-[2-(4-amidinophenoxycarbonyl)-1-propenyl]benzoic acid N-1-(S), 3-bis(ethoxycarbonyl)propylamide, 4-(4-amidinophenoxycarbonyl)-α-methylcinnamic acid N-[1,1,4-tris(ethoxycarbonyl)-3-butenyl]amide, 4-[4-(2-amidinoethenyl)phenoxycarbonyl]benzoic acid N-ethoxycarbonylmethyl-N-allylamide, 4-(4-amidinophenoxycarbonyl)phenoxyacetic acid N-1-(S), 3-bis(ethoxycarbonyl)propylamide, 4-(4-amidinophenoxycarbonyl)-α-methylcinnamic acid N-1,1,2-tris(ethoxycarbonyl)ethylamide, 4-[2-(4-amidinophenoxycarbonyl)-1-propenyl]benzoic acid N-ethoxycarbonylmethyl-N-allylamide, 5-[4-(4-amidinophenoxycarbonyl)phenyl]-2,4-pentadienoic acid N-1-(S), 3-bis(ethoxycarbonyl)propylamide, 5-[4-(4-amidinophenoxycarbonyl)phenyl]-2,4-pentadienoic acid N-ethoxycarbonylmethyl-N-allylamide, 4-(4-amidinophenoxycarbonyl)-α-methylcinnamic acid N-[1,1-bis(ethoxycarbonyl)-3-butenyl]amide, 4-[2-(4-amidinophenoxycarbonyl)-1-methylethenyl]benzoic acid N-1-(S), 3-bis(ethoxycarbonyl)propylamide, 4-[2-(4-amidinophenoxycarbonyl)-1-methylethenyl]benzoic acid N-ethoxycarbonylmethyl-N-allylamide, 3-[4-(4-amidinophenoxycarbonyl)phenyl]-2-ethoxycarbonyl-2-propenoic acid N-1-(S), 3-bis(ethoxycarbonyl)propylamide, 3-[4-(4-amidinophenoxycarbonyl)phenyl]-2-ethoxycarbonyl-2-propenoic acid N-ethoxycarbonylmethyl-N-allylamide, 4-(4-amidinophenoxycarbonyl)-α-methylcinnamic acid N-2-dimethylaminoethylcarbamoylmethyl-N-allylamide, 4-(4-amidinophenoxycarbonyl)-α-methylcinnamic acid N-2-dimethylaminoethoxycarbonylmethyl-N-allylamide, 4-(4-amidinophenoxycarbonyl)-α-methylcinnamic acid N-4-amidinophenoxycarbonylmethyl-N-allylamide, 4-(4-amidinophenoxycarbonyl)-α-methylcinnamic acid N-1,1-bis(ethoxycarbonyl)methylcarbamoylmethyl-N-allylamide, 4-(4-amidinophenoxycarbonyl)-α-methylcinnamic acid N-(diallylcarbamoyl)methyl-N-allylamide, 4-(4-amidinophenoxycarbonyl)-α-methylcinnamic acid N-(i-(S)-ethoxycarbonyl-3-methylbutyl)-N-ethoxycarbonylmethylamide, 4-(4-amidinophenoxycarbonyl)-α-methylcinnamic acid N-3-methylbutyl-N-2-(ethoxycarbonyl)ethylamide, 4-(4-amidinophenoxycarbonyl)-α-methylcinnamic acid N-cyclohexyl-N-2-carboxyethylamide, 4-(4-amidinophenoxycarbonyl)-α-methylcinnamic acid N-2-methoxyethyl-N-ethoxycarbonylmethylamide, 4-(4-amidinophenylcarbamoyl)-α-methylcinnamic acid N-allyl-N-carboxymethylamide, or 4-(4-amidino-1-methoxyphenoxycarbonyl)benzoic acid N-1,1-bis(phenylmethyl)methyl-N-3-phenylpropylamide.

12. A compound according to claim 1, which is 2-[4-(4-amidinophenoxycarbonyl)phenylmethylimino]-2-(N-benzyl-N-methylamino)acetic acid ethylester, or 2-{N-[4-(4-amidinophenoxycarbonyl)phenyl]methyl-N-benzylamino}acetic acid ethyl ester.

13. A compound according to claim 1, which is ethyl 1-[4-(4-amidinophenoxycarbonyl)phenylmethyl]-1-(3-phenylpropyl)phosphinate, or diethyl 2-[4-(4-amidinophonoxycarbonyl)phenyl]ethenylphosphonate.

14. A compound according to claim 1, which is 4-(4-amidionophenoxycarbonyl)-α-methylcinnamic acid N-(2,3,4,5-tetrahydro-fran-2-yl)methyl-N-carboxymethylamide.

15. A compound according to claim 1, which is 4-(4-amidinophenoxycarbonyl)-α-methylcinnamic acid N-(4-piperidinylmethyl)-N-carboxymethylamide.

16. A compound according to claim 1, which is 4-(4-phenylpiperidinylmethyl)benzoic acid 4-amidinophenyl ester, or 4-(2-ethoxycarbonylindolylmethyl)benzoic acid 4-amidinophenyl ester.

17. A compound according to claim 1, which is 4-(2-phenylimidazolylmethyl)benzoic acid 4-amidinophenyl ester.

18. A compound according to calim 1 wherein a compound of the formula (IB) is in the form of a non-toxic acid addition salt.

19. A process for the preparation of a compound of formula (IB):

20. A method for the prevention and/or treatment of diseases induced by leukotriene B4, phospholipaseA2, or trypsin, which comprises administering to a patient an effective amount of a compound of the formula (IB) depicted in claim 1 a non-toxic salt thereof, or a non-toxic acid addition salt thereof.

21. A method for the prevention and/or treatment of diseases induced by leukotriene B4, which comprises administering to a patient an effective amount of a compound of the formula (IB) depicted in claim 1, a non-toxic salt thereof, or a non-toxic acid addition salt thereof.

22. A method for the prevention and/or treatment of diseases induced by phospholipaseA2 or trypsin, which comprises administering to a patient an effective amount of a compound of the formula (IB) depicted in claim 1, a non-toxic salt thereof, or a non-toxic acid addition salt thereof.

23. A method for the prevention and/or treatment of diseases of inflammation or allergy induced by leukotriene B4, which comprises administering to a patient an effective amount of a compound of the formula (IB) depicted in claim 1, a non-toxic salt thereof, or a non-toxic acid addition salt thereof.

24. A method for the prevention and/or treatment of diseases induced by leukotriene B4, which comprises the administration to a patient of an effective amount of a compound of formula (IA):

25. A method for the prevention and/or treatment of diseases of inflammation or allergy induced by leukotriene B4, which comprises administering to a patient an effective amount of a compound of the formula (IA) depicted in claim 24, a non-toxic salt thereof, or a non-toxic acid addition salt thereof.

26. A pharmaceutical composition which comprises, as active ingredient, an effective amount of a compound of the formula (IB) depicted in claim 1, a non-toxic salt thereof, or a non-toxic acid addition salt thereof, with a carrier or coating.